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Sleep disruption influences biological processes that can facilitate carcinogenesis. 
However, studies examining the relationship between sleep disruption and cancer risk 
have been inconclusive. This retrospective cohort study used de-identified data from the 
Veterans Administration (VA) electronic medical record to test the hypothesis that sleep 
disorder diagnoses among Veterans seeking care in the Southeast United States Service 
Network are associated with increased risk for cancer of the prostate, breast, colorectum, 
or total cancer (1999-2010, N=663,869). Sleep disorders were defined as patients with an 
in- or out-patient diagnosis as specified by the International Classification of Sleep 
Disorders. Cancer cases were defined as patients identified in the VA Tumor Registry 
during the follow-up period with a histologically confirmed primary tumor (any stage, 
excluding benign or in situ tumors). The relationship between a prior sleep disorder 
diagnosis and cancer incidence was summarized using extended Cox regression analyses 
with sleep disorder diagnosis as a time-varying co-variate. Sleep disorders were identified 
among 56,055 (8%) of eligible patients; sleep apnea (46%) and insomnia (40%) were the 
most common diagnoses among those with sleep disorders. There were 18,138 cancer 
diagnoses in the study population (42% prostate, 12% colorectal, 1% female breast, 46% 
other). Hazard ratios (HRs) for any cancer diagnosis ranged from 1.34 to 1.69 among 
patients with a diagnosed sleep disorder relative to those without sleep disorders, after 
adjustment for the effects of age, sex, state of residence, and marital status. There was a 
tendency for increased cancer risks with increasing sleep disorder duration (1-year HR: 
iv 
 
1.04, 95% confidence interval [CI]: 1.03-1.06), (5-year HR: 1.23, 95% CI: 1.16-1.32), or 
(10-year HR: 1.52, 95% CI: 1.34-1.73). Results among patients with only sleep apnea,  
insomnia, or all other sleep disorder diagnoses were similar to those for all sleep 
disorders combined. Results from this study suggest that Veterans with a diagnosed sleep 
disorder have an increased cancer risk, and that risk increases with increasing sleep 
disorder duration. Optimal sleep and appropriate sleep disorder management represent 
modifiable risk factors that may facilitate cancer prevention. 
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Sleep has been established as a critical pillar to good health.  Short term effects of 
insufficient sleep or poor quality sleep include fatigue, malaise, and decreased cognitive 
function [1]. Chronic illnesses such as diabetes, cardiovascular disease, obesity, and 
hypertension, as well as psychiatric disease, including post-traumatic stress disorder, 
mood disorders, and depression, have been associated with sleep disorders in 
epidemiologic studies [2-9]. In addition, both long (more than 9 hours) and short sleep 
(less than 5 hours) have been linked with higher overall mortality [4]. Impaired immune 
function and metabolic pathways related to obesity have both been proposed as plausible 
biological models that may explain how poor sleep can lead to cancer development [10]. 
The Veteran population, which represents 20 percent of the United States population 
[11], is a predominantly male, middle-aged population with a high occurrence of chronic 
and psychiatric disease that increase medical care costs [5, 12]. In this study we sought to 
characterize the potential relationship between sleep disorder diagnoses and cancer 
incidence among veterans in the southeastern United States (US).  
 
The relationships between sleep disruption and mortality or chronic disease risk 
have been evaluated, but studies evaluating potential links between sleep disruption and 
cancer risk are limited. The role of circadian disruption as a potential breast cancer 




occur among some cancer patients prior to initiation of chemotherapy [16-19], or among 
cancer patients without anxiety [17], suggesting that these symptoms may not be 
associated with the trauma and stress of a cancer diagnosis and may possibly precede 
tumor development. Sleep disruption is common among shift workers and shift work has 
been associated in past studies to cancers of the breast, prostate, and colon [20-26], which 
has led to its designation as a probable human carcinogen [27, 28]. However, it is unclear 
whether sleep disruption per se, or related biological processes, or a combination of these 
perturbations actually increases cancer risk among shift workers or in other populations 
with disrupted sleep. Associations between sleep disruption, immune system 
dysregulation and inflammation have been described [7].
 
Chronic inflammation is a risk 
factor for some cancer types, particularly colon cancer [29, 30].
 
The demonstrated 
association of sleep disorders and sleep disruption and several different types of chronic 
disease as well as increases in mortality [2-9], the high rates of self-reported sleep 
disruption among Veterans [5, 6], and the fact that cancer is the second leading cause of 
mortality in the United States [31-33], provides a rationale for studying the relationship 
between sleep disorder diagnoses and cancer incidence. Recent studies have primarily 
evaluated breast cancer risk and sleep disruption with varying results, indicating that 
continued research is relevant and needed to determine the relationship and biologic 
mechanism that could be present. Many studies have used self-reported sleep disorder 
status as opposed to clinical sleep disorder diagnosis, which is less reliable for assessment 
of exposure. 
The Veterans Health Administration (VHA) maintains an extensive electronic 




database allows for cost-effective and timely examination of this study’s hypothesis that 
patients with sleep disorders are at increased risk of cancer (breast, prostate, colorectal, 
other, or total) compared to those with no sleep disorder history.  The study used de-
identified data to perform a retrospective cohort study of 663,869 Veterans in the 
Southeastern United States (VISN-7) who were seen at VHA facilities between January, 
1999 and July, 2010.  The specific aims are presented below: 
 
AIM 1: Using descriptive epidemiology, determine the frequency and severity of sleep 
disorder diagnosis among patients in the VISN-7 network from 1999 through 2010. 
 
AIM 2: Conduct a retrospective cohort study to test the hypothesis that individuals with 
sleep disorder diagnoses are at an increased risk for cancers of the female breast, colon, 
prostate, other sites combined, and all cancers combined. 
 
AIM 3: Determine whether VHA patients with an increased duration or severity of sleep 
disorder diagnosis are at greater risk for the development of breast, colorectal, prostate, 
other, or all cancer combined compared to those with less severe, or shorter sleep 







Short sleep of less than five to six hours per night or long sleep of more than nine 
hours per night can increase mortality and chronic disease risk [4, 34-37]. A “U-shaped” 
relationship has been identified for sleep duration in relation to mortality, which is similar 
to other risk factors for chronic disease and mortality, such as physical activity, diet, and 
overall poor health [38]. Cancer is a leading cause of death in the US, and has been 
linked to many of the same lifestyle risk factors [4, 38]. The relationship between sleep 
disruption and cancer or overall mortality has been evaluated [4, 34, 36, 38, 39], although 
few studies have examined the association between diagnosed sleep disorders, or sleep 
disorder duration or severity, in relation to cancer [40]. 
EPIDEMIOLOGY OF PROSTATE CANCER 
Prostate cancer (PCa) is the most common noncutaneous cancer in the world [41, 
42]. It also is the most common cancer type and the second leading cause of cancer 
related death after lung cancer among men in the US [43]. The 5-year survival rate when 
PCa is caught in the early stages is 100% [41, 42], yet the US population is still 
disproportionately affected by this incidence of disease and mortality. The consumption 
of a western diet high in saturated fats has been noted to increase the risk of cancer and 





PCa affects African-American (AA) men disproportionally to European-American (EA) 
men with incidence of disease just over 1.5 times more likely [42] and mortality 
approximately twice as likely [45]. The elderly are also disproportionally affected by 
disease with roughly 65% of cases occurring in persons over 65 years of age [42]. A 
family history of prostate cancer also significantly increases the risk of disease [46]. With 
developed countries being so highly affected by disease, a better understanding of 
treatment and co-morbidities of PCa is needed to decrease the global mortality and 
impacts of this disease.   
EPIDEMIOLOGY OF BREAST CANCER 
Breast cancer (BrCa) is one of the most disparate cancers among racial groups.  
EA women are typically diagnosed with lower stage and grade of disease with more 
favorable outcome than occurs with AA [47-50] and Hispanic women [47].
 
 BrCa 
survival in the United States (US) has been shown also to be strongly linked to socio-
economic status (SES) [51-56]
 
such that women with less education, who are 
unemployed, are more likely to be diagnosed at a later stage of disease [57-62]. The late 
stage of diagnosis among those with lower SES is likely due to lower rates of 
mammography screening and slower follow-up to abnormal screenings due to a lack of 
health care access or similar barriers to care [50, 63-66]. AA women are also 
disproportionally affected by disease with higher grade tumors being diagnosed at 
younger ages, and with shorter survival times, yet even after adjustments for tumor 
characteristics, a poorer outcome can still be expected [52, 54, 67]. Women with 
extremely dense breast tissue or who with a close relative with a history of breast cancer 




oral contraceptive use, nulliparity, or first birth at 30 years or older have all been 
associated with an increased risk of breast cancer as well [68]. Breastfeeding, birth of 3 
plus children, and first menarche at or after 15 years of age have all been shown to 
decrease the risk of cancer [68]. Since known risk factors only account for a fraction of 
breast cancer cases, more research is needed on other possible risk factors such as sleep 
disorders.  
EPIDEMIOLOGY OF COLON CANCER 
Colon cancer is the third most commonly diagnosed cancer and the third leading 
cause of cancer related deaths among men and women in the US [43]. Decreases in colon 
cancer incidence and mortality have occurred in the United States due to widespread use 
of colonoscopies as a primary prevention and detection method [69, 70]. There is a 
known increase in incidence with age and a strong link between healthy lifestyles and 
disease prevention [71, 72]. Diets high in fat and calories and those low in fiber, vitamin 
C, and calcium are known to increase cancer risk. In addition, high consumption of 
alcohol and frequent smoking has also been shown to increase risk. Lifestyles that 
include limited physical activity are at an increased risk as well [73]. Those affected by 
colon cancer tend to have more comorbid conditions then those who are not [74]. 
Differences in incidence and severity have also been noted between racial groups [42, 75-
78]. AAs with colon cancer tend to be diagnosed at later stages of disease, which can be 
at least partially attributed to variations in screening practices, treatments after diagnosis, 
and follow-up surveillance. Though much is known and understood about colon cancer, 




prevention method [74]. This leads to the question of what other biologic factors, 
including sleep disorders, may influence the development of disease.   
EPIDEMIOLOGY OF SLEEP DISRUPTION  
The average human spends about approximately a third of their life sleeping 
which is essential for the body’s physiological balance and the brain’s memory 
consolidation [79]. The optimal amount of sleep that has been associated with decreased 
morbidity [80-83] and mortality [36, 84-88] is 7 to 8 hours.  Sleep is pivotal to regulation 
of the body’s endocrine [81, 83], cardiovascular [81], and metabolic processes [82]. An 
increase in the risk of accidents in and out of the workplace, absenteeism from school and 
workplace, and total health care costs has been associated with sleep disturbances [89]. 
Depression and anxiety disorders are commonly found in sleep disrupted patients, though 
the order in which these diseases affect a patient is debated as both are commonly linked 
to other co-morbidities [90-92]. Low SES has been found to be common among people 
likely to get less than 7 hours of sleep per night, bringing into question whether sleep 
disruption impacts are associated with chronic diseases that tend to be more common 
among those with low SES relative to those in higher SES categories [84, 87, 88]. 
Melatonin produced primarily by the pinal gland and has been found to be related to 
various aspects of the body’s circadian regulation. Altered melatonin production may 
impact sleep, which can affect both the sleep/wake cycle as well as the quality of sleep 
achieved [93, 94].
 
Sleep disruption is present in approximately 75% of patients suffering from Post-
Traumatic Stress Disorder (PTSD) which is about 20% higher than those without PTSD 




varying forms including difficulty falling asleep and staying asleep [99, 100]. Among 
Veterans without PTSD, only 63% had trouble with sleep disruption though this was still 
higher than the civilian population (at 53%) [99, 100]. Sleep disturbances may be 
prolonged by PTSD and may generally predate PTSD, possibly contributing to later 
development under stressful conditions [101]. Rapid eye movement (REM) sleep in 
particular is considered to be essential for emotional processing and daily brain 
functioning and is thought to be most disrupted by PTSD [102, 103]. Due to this, sleep 
disruption while suffering from PTSD can exacerbate both disorders.   
SLEEP DISRUPTION AND CANCER 
Few studies have evaluated the potential association between sleep disruption and 
cancer development, and results among those studies, have been inconsistent. No 
association between sleep duration and cancer was found in several studies [104, 105].
 
Results from the Finnish Twin Study indicated that long sleep was protective while short 
sleep was not found to have any effect on cancer risk [106]. An increased risk of cancer 
also has been noted among those with short sleep and those with both non-apnea sleep 
disorders and apnea sleep disorder [40, 107-109]. To compound the complexity and 
variation of these results, the cancer specific analyses completed to date have equally 
varying results. 
An increased risk of colon cancer has been associated with both long sleep [110, 
111] and short sleep duration [111, 112]. Odegaard et al. also noted a protective effect 
among those with 6-8 hours of sleep duration per night [113], whereas Thompson et al. 




Breast cancer studies have had the most consistency of any cancer type with the 
majority of studies finding no association between duration, quality, or sleep disruption 
and BrCA risk [104, 110, 114-116].
 
However, a study of Chinese women in Singapore 
[117] and the Ohaski cohort of Japanese women [118] both found an inverse association 
between postmenopausal breast cancer risk and long sleep duration. McElroy, et al. also 
found that long sleep was associated with a moderate increase in BrCA risk while short 
duration had no association [119]. PCa studies are more limited with finding so far 
suggesting that sleep disruption and short sleep duration both contribute to increased 
cancer risk [120, 121].
 
High estrogen levels are a risk factor for breast cancer and in some cases low 
estrogen levels have been found in women with elevated melatonin concentrations [122]. 
This is noteworthy since melatonin has been linked to the quality and duration of sleep 
achieved [94]. A Singapore study supports previous work that hypothesized that 
melatonin’s possible protective effect on breast cancer risk may be estrogen related [117, 
122]. Melatonin has also been hypothesized to have a similar inverse relationship with 
prostate cancer as well [121, 123-125]. In vitro studies in both breast and prostate cancer 
cells lines showed that melatonin has an antiproliferative effect [125]. The Ohsaki Cohort 
of Japanese men found a significant inverse relationship between sleep duration and 
prostate cancer risk [118].
 
In addition, men who reported trouble falling asleep or staying 
asleep have also be found to be at a greater risk of PCa incidence [120].
 
These and other 
[10, 126]
 
studies are limited and leave in question the biologic mechanism for an effect of 






SHIFT WORK AND CANCER 
Shift workers have been shown to have significant sleep loss, fatigue, and 
circadian disruption, and they have higher rates of injuries and accidents, disrupted 
lifestyles, and higher risks of gastrointestinal, reproductive, and cardiovascular disease [6, 
127-129]. Shift workers also have been shown to have changes in melatonin levels, 
immune system function, cortisol, and pro-inflammatory cytokine secretion, which are all 
known to increase cancer risk [6, 129]. The International Agency for Research on Cancer 
(IARC) has designated shift work as a probable human carcinogen [27]
 
based off recent 
research showing that shift workers are at an increased risk of colon, breast, prostate, 
endometrial, and lymphatic system cancers [20-26, 28, 130].
 
CO-MORBIDITIES AND OTHER RISK FACTORS 
Long-term effects of sleep deprivation include obesity, hypertension, reduced 
parasympathetic tone, increased pro-inflammatory cytokine secretion, increased oxidative 
stress, and increased evening cortisol and insulin levels [6]. These effects are thought to 
be a form of allostatic load caused when the body is deprived of sleep over time and 
contributes to the development of chronic disease [6].  Depression and mood disorders 
have also been shown to be strongly linked to sleep disruption and sleep quality [92] and 
quantity have been associated to changes in the immune response and inflammation [131, 
132]. Several experimental studies have shown that even as little as half a night of sleep 
loss can increase blood pressure in patients with hypertension and pre-hypertension and 
others have linked sleep disruption with cardiovascular disease [133-136]. Long sleep (>8 
hours) increases risk of stroke by as much as 50% among those 31 and older compared to 




immune, and mood disorders that are associated with sleep disruption is convincing to 
continue to study the effects of poor sleep quality and quantity on other adverse health 
outcomes including cancer.  
VISN-7 AND VETERANS 
The Veterans Integrated Service Network-7 (VISN-7) is the medical network that 
serves approximately 1.3 million veterans. VISN-7 includes medical centers and 
outpatient clinics covering veterans care in most of Alabama, Georgia, and South 
Carolina [135]. Recent VA statistics indicate that about 40% of veterans are 65 and older, 
the median age of all living veterans is 60, and 88% are male, making the population 
accessing the Veterans Health Administration (VHA) services a predominantly aging-
male population [11]. The VISN-7 has seen one of the highest growth increases among 
all the country’s VISN groups. This increase has created a strain on the type and amount 
of care the medical centers are capable of providing [135].
 
The VHA uses an electronic medical record system that has been in place for over 
a decade called VistA (Veterans Health Information Systems and Technology 
Architecture) [138]. Since 1997, this includes a Computerized Patient Record System 
(CPRS) which provides a single interface between all medical centers to provide tracking 
of all medical care given to each patient [137].
 
The VISN-7 includes 9 tertiary care 
medical centers, 14 community based outpatient clinics (CBOCs), and 18 primary care 
clinics [135]. VISN-7 has a large percentage of patients in the chronic care category 








This study used data in the VISN-7 Veteran’s health database to conduct a 
retrospective cohort study to determine if veteran’s with sleep disorders are at an 
increased risk of cancer. All statistical analysis was performed using SAS 9.3 (SAS 
Institute, Inc, Cary, NC). IRB approval from the Dorn Department of Veterans Affairs 
Medical Center (DVAMC) and the University of South Carolina was obtained. The data 
was requested from and stored based on VISN-7 data warehouse protocols. The 
association of sleep disorders and a later cancer diagnosis was evaluated using Cox 
Extended regression models. Adjustments were made for co-morbidities, gender, age, 
race, and state of residence. The possibility of a dose-response relationship was evaluated 
with consideration of length of treatment and severity of sleep disorder in relation to 
cancer diagnosis.  
STUDY POPULATION 
A de-identified file of all active medical records between January, 1999 and July, 
2010 was obtained from the VISN-7 Corporate Data Warehouse. To be included, patients 
must have been seen at least once at a VA medical facility or clinic during this time 
frame. The data extraction from the VISN-7 Corporate Data Warehouse was requested in 
the format outlined in Table 3.1. Any patient with a cancer diagnosis prior to the 




(ICD-9 152), skin (ICD-9 172-173), uterus (ICD-9 179 and 182), cervix (ICD-9 180), 
thyroid (ICD-9 193), lips, oral cavity, and pharynx (ICD-9 140-149), Hodgkin’s 
lymphoma (ICD-9 201), as well as in situ (ICD-9 230-234) and benign (ICD-9 210-229) 
tumors were excluded. In addition, patients younger than 18 years of age or those without 
age information were excluded. Original data extraction (N=698,871) was performed by 
a VISN-7 data manager. After all exclusions were applied, 663,869 eligible patients were 
included in the analysis. Survival time was defined as the time from entry into the cohort 
until cancer diagnosis or censoring. Partients who were only seen once at a VISN-7 
facility were assigned a total time of 0 months and considered censored at the time of 
entry. 
First occurrence of outpatient sleep disorder diagnosis was identified by ICD-9 
codes for sleep disturbance (ICD-9 780.50-59), nonorganic sleep disorders (ICD-9 
307.40-49), organic insomnia (ICD-9 327.00-09), organic hypersomnia (ICD-9 327.10-
19), organic sleep apnea (ICD-9 327.20-29), and circadian rhythm sleep disorders (ICD-9 
327.30-39) based on American Academy of Sleep Medicine International Classification 
of Sleep disorders (ICSD) categories [139]. Sleep disorder cases were defined as patients 
with at least two occurrences of the diagnosis 30 or more days apart. Covariate 
information available for the analysis included: age, gender, marital status, co-morbid 
diagnoses, medication use, medical procedures combat deployment information, income, 
and other physician noted factors. Data for combat deployment, smoking status, income, 
and body mass index were not available. Body mass index is a known deficiency in the 
VHA data with weight being more consistently recorded in the medical record then 




hypertension, and stroke, as well as depression, PTSD, and other mental disorders. The 
state of residence was assigned to each participant to adjust for spatial variation in social-
economic or other risk factors. Veteran Medicare data were merged by the VISN-7 data 
manager using the social security number to assign race information, when available, for 
each study participant based on VA Information Resource Center (VIReC) 
recommendations [141]. VIReC identified this as best practice for race data completeness 
as it improves data completeness to 75% or higher with use of the VA Medicare data 
source [142]. 
Cases of prostate (ICD-9 185), female breast (ICD-9 174), colorectal (ICD-9 153-
4), and all combined cancers cases diagnosis were obtained. All combined cancer cases 
included prostate (ICD-9 185), female breast (ICD-9 174), colorectal (ICD-9 153-4), lung 
(ICD-9 162), pancreatic (ICD-9 157) kidney (ICD-9 189), brain (ICD-9 191), bladder 
(ICD-9 188), liver (ICD-9 155), ovarian (ICD-9 183), esophageal (ICD-9 150), and 
gastric (ICD-9 151) cancers. Cancer diagnosis was validated by the VISN-7 data manager 
by merging these data with the national VA tumor registry by social security number to 
confirm the cancer diagnosis and verify that it was a primary cancer. 
AIM 1 – DESCRIPTIVE EPIDEMIOLOGY OF SLEEP DISORDERS 
 The frequency and distribution of all variables was to determine the general 
characteristics of the population. A chi-squared distribution was used to evaluate whether 
categorical population characteristics differed among those with and without sleep 
disorders, and t-tests were used to evaluate continuous data. Sleep disorder frequency and 
distribution was used to characterize rates of diagnosis, types of disorders, and place of 




significance. Sleep disorder treatment and duration of sleep disorder diagnosis were 
evaluated to determine if they influenced the relationship between sleep disorder 
diagnoses and cancer risk. The cumulative sleep disorder treatment variable was 
developed by combining counts of sleep disorder prescriptions, sleep procedures and 
surgeries into a single continuous variable.  Participants were grouped into a four-level 
categorical variable based the distribution of tertiles among those with values greater than 
zero:  no treatment (0 prescriptions), mild level of treatment (1 prescription), moderate 
level of treatment (2-18 prescriptions), and high level of treatment (19-1150 
prescriptions). A categorical variable for sleep disorder duration was created in a similar 
manner by grouping those with sleep disorder duration of 0 months into a single group 
and then creating tertiles among years of sleep disorder duration (0, 1-26, 27-62, 63-149 
months).   
Sleep disorders were grouped into the following categories: all sleep disorders, 
insomnias, sleep apneas, and all others. Race was grouped into European-American 
(white), African-American (black), and other/unknown due to a low number of 
individuals in any one race category other than European-American and African-
American. Co-morbid conditions (e.g. mental disease, diabetes, hypertension, stroke, 
cardiovascular disease) were defined using an indicator variable if the condition occurred 
at least once during the study period. For analysis purposes, the co-morbid conditions of 
hypertension, stroke, and cardiovascular disease were combined into a single categorical 
variable if any of them existed in a patient’s medical history. Age at entry was grouped 
into a categorical variable (18-34 years, 35-44 years, 45-54 years, 55-64 years, or ≥65 




AIM 2 AND AIM 3 – RETROSPECTIVE COHORT STUDY DATA ANALYSIS 
The relationship between sleep disorder diagnosis, treatment, or duration and 
cancer risk was initially evaluated using the Kaplan Meier (Proc Lifetest) procedure in 
SAS to develop cumulative survival statistics for each exposure and cancer site at three, 
five, seven, ten and 12.5 years of follow-up. The data for female breast cancer cases in 
conjunction with those in the ‘other’ sleep disorder group were too sparse for evaluation. 
Kaplan Meir plots were used to graphically display the proportion of those without the 
cancer endpoint among participants with and without sleep disorders and across levels of 
duration or treatment. Because of evidence that the proportionality assumption was not 
met (because of crossing or merging Kaplan Meier curves), subsequent analyses were 
performed using the Cox extended model with time-dependent variables in SAS. The 
Phreg procedure was applied with the /rl option to estimate hazard ratios and 95% 
confidence intervals for each combination of sleep disorder and cancer outcome. Cancer 
cases were censored at the time of diagnosis.  
Possible covariates for inclusion in the Cox proportional hazards models were 
initially evaluated using individual Kaplan Meier estimates to identify variables 
associated with each cancer endpoint for subsequent inclusion in the multivariable 
extended Cox proportional hazards analyses. Hazard ratios and 95% confidence to test 
the hypotheses stated in Aims 2 and 3 were performed for each combination of the sleep 
disorder exposure and cancer endpoint using crude, adjusted, and stratified models. 
Covariates were included in a multivariable (adjusted) Cox proportional hazards models 
if their inclusion resulted in at least a 10 percent change in the effect estimate for sleep 




Interaction terms with the exposure variable were used to evaluate variables for effect 
modification including race and co-morbid disease (diabetes, mental disorders, 
cardiovascular disease, hypertension, and stroke). If evidence effect modification was 
observed, these covariates were excluded from the base models and instead subsequent 
analyses were stratified by these covariates. This was the case for the co-morbid 
conditions.  
The extended Cox method used for Aim 2 allows for a more accurate evaluation 
of the relationship between exposure and outcome when the proportional hazards 
assumption is not met. The method included sleep disorder diagnosis as a time-varying 
covariate. Using this method, sleep disorder diagnosis was not assessed until the point in 
time that it was diagnosed (the first of the two occurrences at least 1 month apart). This 
method was adapted from a previously described study that assessed the exposure at the 
point of occurrence, but not prior to it [143]. This approach allowed for the assessment of 
the association between sleep disorders and cancer incidence continuously over time 
instead of only once.  
Aim 3 attempted to evaluate the potential dose-response relationships between of 
sleep disorder severity and cancer incidence using two derived variables that served as 
surrogate measures. First, the total time since sleep disorder diagnosis was used to 
capture the duration of the sleep disorder diagnosis. Second, the total number of sleep 
disorder prescriptions, procedures and surgeries was used to define a ‘cumulative 
treatment’ variable. Time since diagnosis of a sleep disorder and the cumulative number 




analyses. Duration of sleep disorder diagnosis was used in a time-varying model where it 
was evaluated for its dose-response in relation to cancer incidence. 
Sleep disorder duration provided for an assessment of the possible latencies 
between sleep disorder diagnoses and cancer incidence, and served as a method for 
avoiding reverse causality. A time-varying model was developed where sleep disorder 
exposure was assessed after diagnosis of sleep disorder disease at each failure point in the 
model [47]. This allowed for a more accurate assessment of the latency period between 
sleep disorder diagnosis and cancer incidence.   
The relationship between cumulative sleep disorder treatment and cancer 
incidence could not be modeled in the same way as the relationship between sleep 
disorders duration and cancer risk since a sleep disorder diagnosis was not required for 
the assessment of treatment. Because some of these prescriptions and procedures can also 
be used to treat other conditions, it was essential that all participants be evaluated to 
prevent biased results. Therefore, in this analysis, all study participants were evaluated to 
determine whether the frequency of prescriptions and procedures was associated with a 
cancer diagnosis, regardless of their sleep disorder status. A Cox extended model was 
used where the cumulative treatment was multiplied by the total time in the study to 
account for the lack of proportionality noted previously.    
 Stratified analysis were conducted on all final models for sleep disorder and 
cancer incidence, sleep disorder duration and cancer incidence, and sleep disorder 
treatment and cancer incidence to account for the potential independent association of 
race or co-morbid conditions on sleep disorder exposure and cancer incidence. The 




were evaluated. Similar co-morbid conditions were grouped together into mental 
disorders and mental retardation as one group and hypertension, stroke, and 
cardiovascular disease in a second group. The co-morbid condition of diabetes was used 




Table 3.1:  VISN-7 Data Warehouse Variable Request List 
 
Variable Type Description 
Gender Male  
Female 
Unknown 
Race/Ethnicity Race/Ethnicity information from linked Medicare database 
for complete ethnicity information 
Age Age at entry into dataset 
Death Status Whether the participant was alive or dead at the point of 
censoring. 
State_Residence State Name at entry into dataset 




Sleep Disorder  ICD-9 Code list of diagnosed sleep disorders  including:  
Each disease is coded as own category or column with 
1 = Yes / 0 = No.   
Sleep Disturbance 780.50-59 
Nonorganic sleep disturbances 307.40-49 
Organic Insomnia 327.00-09 
Organic Hypersomnia 327.10-19 
Organic Sleep Apnea 327.20-29 
Circadian Rhythm Sleep Disorders 327.30-39 
Primary Cancer ICD-9 Code list of diagnosed primary cancer: 
Each disease is coded as own category or column with 
 1 = Yes / 0 = No 
Prostate Cancer 185 
Female Breast Cancer 174 
Colorectum Cancer 153-154 
Non-Hodgkin’s Lymphoma 200, 202 
Lung Cancer 162 
Pancreatic Cancer 157 
Leukemia 204-208.9 
Kidney Cancer 189 
Brain Cancer 191 
Bladder Cancer 188 
Liver Cancer 155 
Ovarian Cancer 183 
Esophageal Cancer 150 
Gastric Cancer 151 
Cancer Stage SEER cancer stage 
Co-Morbid_Cond ICD-9 Code list of co-morbid conditions to include: 





 1 = Yes, with disease / 0 = No without disease.   
Diabetes 249-250 
Mental Disorders 
      Mental Disorder/ Organic Psychotic Conditions (290-
294): 
1. Dementias (290) 
2. Alcoholic & Drug Psychoses (291-292) 
3. Transient & other Organic psychotic conditions 
(293-294) 
      Mental Disorders/ Other Psychoses (295-299):  
1. Schizophrenic disorders (295) 
2. Episodic Mood Disorders (296) 
3. Paranoid states (297) 
4. Other Nonorganic Psychoses and Psychoses with 
Origin specific to childhood (298-299) 
      Mental Disorders/ Neurotic, Personality and & other 
non-     Psychotic  (300-316): 
1. Neurotic Disorders (300) 
2. Personality Disorders (301) 
3. Sexual Deviations and Disorders (302) 
4. Alcohol and Drug Dependence (303-304) 
5. Nondependent abuse of drugs (305) 
6. Physiological malfunction arising from mental 
factors (306) 
7. Special symptoms or syndromes not elsewhere 
classified ( includes eating disorder) (307) 
8. Acute Reaction to Stress (308) 
9. Adjustment Reaction (309) 
10. Specific Non-psychotic Mental Disorders following 
organic brain damage (310) 
11. Depressive Disorders, not elsewhere classified  (311) 
12. Disturbance of conduct, no elsewhere classified 
(312) 
13. Disturbance of emotions specific to childhood 
adolescence (313) 
14. Hyperkinetic syndrome of childhood (314) 
15. Specific Delays in Development (315) 
16. Psychic factors associated with disease elsewhere 
classified (316) 
Mental Retardation (317-319) 
Stroke (434.91) 
Cardiovascular disease (390-459) 
All Hypertension (410-405) 
       Chronic Kidney Disease-related Hypertension (403-
404) 















Rx_Number Number of prescriptions of any type filled for patient which 
are not sleep disorder related 
Total_SleepRx Total quantity of sleep medications prescribed to patients 
Procedures Count  of sleep disorder related procedures performed on 
patient 
Surgeries Count of sleep disorder related surgeries performed on 
patient 











Total_Time Total time since entry into data in months 
Time_SleepCA Total time in months between initial sleep disorder 
diagnosis and initial cancer diagnosis or censoring 
Time_toSleep Total time in months from entry to initial sleep disorder or if 
not sleep disorder to censor 
BMI Body Mass Index or if not available height and weight listed 
separately at six month intervals from entry into dataset.  
Deployment_Combat Number of times deployed or in combat zones 
Rank Former military rank at entry into dataset 
Total_ICD-9 Total number of ICD-9 diagnoses  
Age_Sleep Age at Sleep Disorder Diagnosis 
Age_Cancer  Age at Cancer Diagnosis 
Co-morbid_PRE Number of Co-morbid conditions prior to sleep disorder 
diagnosis 
Co-morbid_Post Number of Co-morbid conditions after sleep disorder 
diagnosis 






If not BMI is available at that time point, hole to next time 
point. 
 
# should change 1-20 for each time point checked during 
duration of study. 
SD_TP# Cumulative time in months since sleep disorder diagnosis at 
assessment point. 
 
# should change 1-20 for each time point checked during 
duration of study. 









The final study population included 663,869 eligible individuals after applying 
inclusion and exclusion criteria (Figure 4.1). At baseline, 66 percent of the study 
participants were over the age of 45 years, 52 percent were married, 88 percent were 
male, and 45 percent were white. Residents of Georgia made up the largest portion of the 
study participants by state (35%). There was a total of 56,055 total sleep disorders (8.4%) 
and 18,181 total cancers (2.7%) during the study period. Insomnias comprised 3.4 percent 
(22,380 cases) of the study population, apneas comprised 3.9 percent (25,602 cases), and 
other sleep disorders 1.2 percent (8,073 cases) (Figure 4.2).  There was an increasing 
trend of sleep disorder diagnoses across the study period (Figure 4.3).     
Baseline characteristics of the study population are presented in Table 4.1. More 
than 50 percent of the study participants had at least one prescription, procedure, or 
surgery that could have been ordered for sleep disorder treatment. One-third (33%) of the 
participants had a diagnosis of cardiovascular disease, stroke, or hypertension, six percent 
had diabetes, and 16 percent had a mental disorder. Participants with a sleep disorder 
diagnosis were more likely to be male (92%) and divorced (19%) compared to those 
without a sleep disorder (Table 4.1). Those without a sleep disorder diagnosis had a 




median of 26 among those with a sleep disorder diagnosis. The distribution of co-morbid 
disease was similar between those with and without sleep disorders, but the median 
number of total co-morbid diagnoses observed among those with a sleep disorder was 
157 compared to a median of 39 among those without sleep disorders (Table 4.2).  
Descriptive statistics for cancer cases are presented in Table 4.3. There were 9,844 (54%) 
cancer cases diagnosed at a localized SEER stage of disease and 1,271 (7%) had a sleep 
disorder diagnosis. Cancer cases were predominantly white (53%), from Georgia (40%), 
male (98%), and married (49.6%). The median age at cancer diagnosis was 64 years with 
30 percent of cases 65 or older at entry into the cohort. Among cancer cases, 69 percent 
received at least 1 sleep disorder related prescription during the study period.   
During the evaluation of descriptive statistics, it was found that some of the 
cancer cases did not have complete stage of disease results from the VA cancer register. 
Cancer cases with missing stage data were compared to the rest of the study population 
using an indicator variable (‘1’ for those without SEER [Surveillance, Epidemiology, and 
End Results Program] data for cancer and a ‘0’ for all others included in the study). 
When this variable was included in the Cox extended model there was no impact on the 
results presented below. Thus, missing cancer stage data was random and infrequent 
enough that it did not affect the study’s results.    
The Kaplan Meir curves consistently showed a merging or crossing of the 
proportion of cancer cases among participants with and without sleep disorder diagnoses 
or sleep disorder treatments over time usually beginning between 7 and 10 years after 
follow-up for each cancer type evaluated (Tables 4.4-4.8). In addition to the tables, 




diagnoses, cumulative treatments, or sleep disorder duration. The Kaplan Meir 
proportions for cancer incidence suggested that any sleep disorder or an insomnia 
diagnosis was associated with an increased risk of all cancer and colon cancer after a 
cross over point. For female breast cancer, there was a tendency towards increased cancer 
incidence among those with all sleep disorders, insomnias, apneas, or those in the other 
sleep disorder diagnosis group, but none of the comparisons were statistically significant 
(Table 4.7). There was an increased risk of all types of cancer incidence with increasing 
levels of the cumulative sleep disorder treatment (Tables 4.4-4.8). Also noted was a slight 
increase in cancer incidence with mild exposure to no exposure for sleep disorder 
duration for all (Table 4.4), colon (Table 4.5), prostate (Table 4.8), and female breast 
cancer (Table 4.7). The all other cancer group showed a decrease in cancer incidence in 
all tests for all sleep disorders, insomnias, apneas, the other sleep disorder group, and 
sleep disorder exposure duration (Table 4.8). The inconsistent nature of these results and 
the merging or change in direction of the cancer probability trends for the Kaplan Meir 
results over time suggest that the proportional hazards assumption was not met, and the 
Cox extended model was applied as an alternative data analysis strategy.  
Results from the crude Cox extended time-varying models showed increased HRs 
among those diagnosed with any type of sleep disorder for each type of cancer evaluated 
(Table 4.9). The adjusted models indicated an increased risk for all cancer, other cancer 
group, and prostate cancer among those with any sleep disorder diagnosis, sleep apnea, 
insomnia, or other types of sleep disorders after adjustment for marital status, state of 
residence, sex (for non-gender specific models), and age. The adjusted models also 




association of colon cancer and insomnia or the other sleep disorder group was noted in 
the adjusted models (Table 4.9). The adjusted model results for female breast cancer 
showed no statistically significant association in relation to any of the sleep disorders 
evaluated.  
When cumulative sleep disorder treatments were evaluated using Cox Extended 
models, a statistically significant increased risk of cancer was observed among categories 
with an increasing number of prescriptions or procedures during the study period for each 
type of cancer that was evaluated (Table 4.10).  For all cancer, there was 26 percent 
higher incidence of cancer among those with at least 25 cumulative treatments, which 
increased to an HR of 2.5 among those with 100 or more prescriptions. A similar 
increasing trend in cancer risk was noted for colon cancer, prostate cancer, female breast 
cancer, and the other cancer group with each level of increasing cumulative treatment that 
was evaluated (Table 4.10). The all cancer, other cancer, and prostate cancer models 
indicated the steepest increases in risk associated with increasing levels of sleep disorder 
treatment, but each cancer type modeled had noteworthy and statistically significant 
increases in risk with increased sleep disorder treatment.   
  When the duration of time since the primary sleep disorder diagnosis was 
considered, there was a statistically significant increased incidence for cancer of the 
prostate, colon, other, or all cancer with longer latency after initial diagnosis of any sleep 
disorder (Table 4.11). For all four cancer types, there was approximately a 50 percent 
increase in the adjusted hazard ratios as the latency of sleep disorder diagnosis increased 




95% CI: 0.96, 1.3 for 1 year) although the association between sleep disorder duration 
and cancer incidence was not statistically significant.  
Each of the models for sleep disorders, duration, and treatment were then 
stratified by race and the co-morbid conditions of diabetes, mental disorders, and a 
category that combined cardiovascular disease, stroke, and hypertension (Tables 4.12-
4.35). The sleep disorder models stratified by race for time-varying all sleep disorder 
diagnoses show an increased risk of all and colon cancer and the other cancer group for 
EA versus AA (Table 4.12). The other/unknown race group had the highest risks for all 
cancer and the all other cancer group (Table 4.12). The models stratified by diabetes 
suggest an overall higher risk of colon cancer for each of the sleep disorder models and 
an overall lower risk of prostate cancer among those with diabetes (Table 4.13-4.15). The 
models stratified by mental disorders showed a lower overall risk or no association for 
each of the cancer types and all sleep disorder groups among those with mental disorders 
(Table 4.20). The sleep disorder models stratified by hypertension, cardiovascular 
disease, or stroke show a higher risk of colon cancer among those with apnea versus 
those without (Table 4.26).   
The sleep disorder duration models stratified by race indicate a similar risk of all 
cancer with sleep disorder exposure among both AA and EAs with increasing cancer risk 
as duration of sleep disorder exposure increases (Table 4.28). For colon cancer and all 
other cancer, only EAs show a significant risk of cancer with exposure (Table 4.28). The 
models stratified by diabetes demonstrate a higher risk of all cancer and colon cancer 
among those with diabetes, a lower risk of prostate cancer, and approximately the same 




lower risk or no statistically significant risk of cancer among those with mental disorders 
compared to those without disorders (Table 4.32). All models stratified by cardiovascular 
disease, hypertension, and stroke show lower or no risk among those with the co-morbid 
condition, except for colon cancer (Table 4.34). The stratified model for colon cancer 
shows higher risk among those with cardiovascular disease, hypertension, and stroke 
(Table 4.34). Sleep disorder duration did not suggest an association with any cancer 
group in the stratified models.  
The treatment models stratified by race showed notably higher all cancer, 
prostate, colon, and all other cancer risk among AAs compared to EAs. This risk for each 
race group is also increased with increasing levels of treatment (Table 4.29). The models 
stratified by diabetes for all cancer, all other cancers, and prostate cancer show a very 
similar risk of cancer between those with and without diabetes, though the risk among 
those with diabetes is slightly higher. The model stratified by diabetes for colon cancer 
shows a similar, but slightly higher risk of cancer among those with diabetes (Table 
4.31). The models stratified by mental disorders show a higher risk of all cancer, colon, 
prostate, and all other cancers among those with mental disorders particularly at higher 
levels of treatment (Table 4.33). The models stratified by cardiovascular disease, 
hypertension, and stroke show similar risk among those with and without the co-morbid 
condition for all cancer, all other cancers, and colon cancer (Table 4.35). For prostate 
cancer, the risk of cancer is higher among those with cardiovascular disease, 
hypertension, and stroke compared to those without, particularly at higher levels of 




no association at one or both levels of stratification for treatment models (Tables 4.29, 













Figure 4.2: Proportion of the population with sleep disorder 
diagnosis among Veterans in the Southeastern United States, 
1999-2010.   
Other includes hypersomnia, parasomnia, arousal disorders, and 
other non-classified sleep disorders. 
No Disease (n=607,814)































Year of Diagnosis 
Figure 4.3:  Number of Primary Sleep Disorder Cases 
Diagnosed by Year for Veterans in the Southeastern United 
States, 1999-2010.   
Other includes hypersomnia, parasomnia, arousal disorders, and 
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 Total Time in Cohort (months): 










   Median 143.0 143.0 143.0 
   Minimum 0 3.0 0 




















Other race refers to: Hispanic, Asian, American Indian, Pacific Islanders, and 
unknown race 
2
All Other Cancer includes: Lung, pancreatic, kidney, brain, bladder, liver, 
ovarian, esophageal, gastric, and melanoma cancers. 
3
Other state includes a small area of Alabama included in VISN-7 as well as 





Table 4.2:  Descriptive statistics of disease exposure Among Veterans in the SE USA 
(VISN-7, 1999-2010). 











































Count of Sleep Disorder 
Prescription and Treatments  













   Median 2.0 26.0 1.0 
   Minimum 0 0 0 
   Maximum 1,150 1,150 1,150 
Sleep Disorder Duration: 
[months (categorical)] 

































Sleep Disorder Duration: 
[months (continuous)]   










   Median 93.0 93.0 0 
   Minimum 0 0 0 
   Maximum 143 143 0 
Total Co-morbid Diagnoses    










   Median 45.0 157.0 39.0 
   Minimum 0 1 0 






Table 4.3:  Descriptive Statistics for Cancer Among Veterans in the SE USA (VISN-7, 
1999-2010). 








   Localized 54.2  
(9,844) 
   Regional 18.6  
(3379) 
   Unknown 6.8  
(1,234) 
Sleep Disorder Type: 




   Insomnias 2.8  
(509) 
   Apneas 3.1  
(568) 
   Other Sleep Disorder Group
2
 1.1  
(194) 
   No Sleep Disorder 93.0  
(16,910) 
 Age Range (years) At Study Entry 




   35-44 7.6  
(1,381) 
   45-54 34.6  
(6,286) 
   55-64 27.2  
(4,945) 
   65 plus 29.8  
(5,428) 
Age (years) at Cancer Diagnosis    




   Median 64.0 
   Minimum 23.0 
   Maximum 100.0 
Race 




   African-American 38.6  
(7,017) 




Variable % (N) 
(1,478) 
 State of Residence 




   Georgia  40.1  
(7,285) 
   South Carolina  33.7  
(6,120) 
   Other 5.7  
(1,041) 
Diabetes 
  Yes 
8.3  
(1,516) 
   No  91.7  
(16,665) 
Mental Disorder/Retardation    




   No 74.4  
(13,527) 
Cardiovascular Disease, Stroke, and/or Hypertension    




   No  53.5  
(9,721) 
 Sex: 




   Female 2.1  
(384) 
   Unknown 0.1  
(20) 
Marital Status:  




   Never Married 7.0  
(1,272) 
   Divorce 24.3  
(4,414) 
   Widowed  11.2  
(2,039) 
   Unknown  7.9  
(1,432) 
Cumulative Sleep Disorder Treatment : 







Variable % (N) 
   Mild Treatment (1) 9.1  
(1,645) 
   Moderate Treatment (2-18)  33.0  
(5,998) 
   Frequent Treatment (19-1150) 27.3  
(4,970) 
Count of Sleep Disorder Prescription Treatments: 




   Median 3 
   Minimum 0 
   Maximum 812 
Sleep Disorder Duration:     
Months (categorical) 




    Mild (1-26) 3.1 
(555) 
    Moderate (27- 62) 2.2  
(406) 
    Severe (63-149) 1.6  
(288) 
 Total Time (months) in Cohort 




   Median 86.0 
   Minimum 0 
   Maximum 150.0 
1
SEER: Surveillance, Epidemiology, and End Results Program. 
2
Other sleep disorders 









Table 4.4: Results of Kaplan Meier Survival Analysis: ALL CANCER, for Veterans in the SE USA (VISN-7, 1999-2010). 
Covariate N 3-year 5-year 7-year 10-year 12.5 year p-Value 
All Sleep Disorders No 607,814 0.005870 0.01030 0.01480 0.023200 0.049300 <0.0001 
 Yes   56,055 0.001090 0.00319 0.00614 0.014400 0.061600  
Apneas No 638,267 0.005650 0.01000 0.01440 0.022800 0.050600 <0.0001 
 Yes   25,602 0.000978 0.00287 0.00552 0.013900 0.046900  
Insomnias No 641,489 0.005630 0.00997 0.01430 0.022800 0.049100 <0.0001 
 Yes   22,380 0.000897 0.00307 0.00618 0.014300 0.079800  
Other Sleep Disorders
1
 No  655,796 0.005510 0.00980 0.01410 0.022600 0.050600 0.0116 
 Yes     8,073 0.001990 0.00452 0.00801 0.015800 0.042200  
Cumulative Sleep 
Disorder Treatment   
No Treatment (0) 273,450 0.006370 0.01010 0.01330 0.018500 0.022200 <0.0001 
 Mild Treatment (1)   51,858 0.006970 0.01180 0.01630 0.025900 0.044300  
 Moderate 
Treatment (2-18) 
171,793 0.006580 0.01210 0.01740 0.028800 0.068200  
 Frequent Treatment 
(19-1150) 
166,768 0.002380 0.00618 0.01100 0.021800 0.066600  
Sleep Disorder Duration 
(months) 
None(0) 608,374 0.005870 0.01030 0.01480 0.023300 0.049300 <0.0001 
 Mild (1-26)    18,755 0.002740 0.006430 0.010800 0.022600 0.139500  
 Moderate (27-62)    18,158 0.000386 0.003000 0.006250 0.014500 0.038100  
 Severe (63-1149)    18,582 0 0 0.001130 0.005930 0.043600  
Age at Study Entry 18-34 102,501 0.000156 0.000225 0.000352 0.000637 0.001390 <0.0001 
 35-44 118,952 0.000674 0.001780 0.003090 0.006710 0.045600  
 45-54 174,996 0.003610 0.007550 0.012500 0.025500 0.065800  







Covariate N 3-year 5-year 7-year 10-year 12.5 year p-Value 
 ≥ 65 162,945 0.011900 0.019100 0.025600 0.035400 0.061400  
State of Residence SC 175,517 0.006530 0.012200 0.018000 0.028400 0.060700 <0.0001 
 GA 237,107 0.006250 0.010700 0.014700 0.024400 0.064200  
 AL 156,268 0.004950 0.008780 0.013400 0.021100 0.039900  
 Other  94,977 0.002420 0.004260 0.006060 0.009340 0.016000  
Race European American 298,339 0.006850 0.012100 0.017300 0.027200 0.050400 <0.0001 
 African-American 173,942 0.007620 0.013400 0.01940 0.03170 0.106300  
 Other/Unknown 191,588 0.001360 0.002730 0.00400 0.00656 0.012400  
Sex Male 583,454 0.006110 0.010900 0.01570 0.02530 0.054700 <0.0001 
 Female 71,610 0.000868 0.001730 0.00241 0.00380 0.013500  
 Unknown 8,805 0.000455 0.000912 0.00114 0.00183 0.016900  
Diabetes No  626,109 0.005320 0.009450 0.01360 0.02180 0.049900 <0.0001 
 Yes 37,760 0.007860 0.014500 0.02100 0.03380 0.062000  
Mental Disorder/ Mental  
Retardation 
No  555,499 0.004960 0.008800 0.01260 0.02000 0.041000 <0.0001 
 Yes 108,370 0.008070 0.014500 0.02140 0.03530 0.097000  
Cardiovascular Disease, 
Hypertension, and Stroke 
No  444,622 0.004340 0.007720 0.01100 0.01770 0.044300 <0.0001 
 Yes 219,247 0.007760 0.013900 0.02030 0.03250 0.063900  
Marital Status Married 342,114 0.005440 0.009630 0.01390 0.02200 0.041000 <0.0001 
 Single  51,846 0.004470 0.007750 0.01160 0.01960 0.048700  
 Divorced  118,148 0.006390 0.012100 0.01750 0.02970 0.064800  
 Widowed  45,455 0.011100 0.019400 0.02730 0.04240 0.085700  
 Unknown 106,306 0.002620 0.004470 0.00636 0.00989 0.059900  
1







Covariate N 3-year 5-year 7-year 10-year 12.5 year p-Value 








Table 4.5: Results of Kaplan Meier Survival Analysis: COLON CANCER, for Veterans in the SE USA (VISN-7, 1999-2010). 
Covariate N 3-year 5-year 7-year 10-year 12.5 year p-Value 
Sleep Disorders:         
All  No 607,814 0.000200 0.000417 0.000741 0.001340 0.022600 0.1072 
 Yes   56,055 0.000036 0.000181 0.000311 0.000774 0.042200  
Apneas No 638,267 0.000193 0.000406 0.000719 0.001310 0.024200 0.3316 
 Yes   25,602 0 0.000159 0.000319 0.000696 0.027900  
Insomnias No 641,489 0.000191 0.000406 0.000722 0.001310 0.022800 0.3967 
 Yes   22,380 0.000045 0.000135 0.000182 0.000765 0.060300  
Other
1
 No 655,796 0.000186 0.000396 0.000704 0.001290 0.024400 0.3288 
 Yes     8,073 0.000125 0.000378 0.000639 0.001050 0.021200  
Cumulative Sleep 
Disorder Treatment  
No Treatment (0) 273,450 0.000067 0.000124 0.000183 0.000250 0.001080 <0.0001 
 Mild Treatment (1)   51,858 0.000176 0.000257 0.000532 0.001020 0.013400  
 Moderate 
Treatment (2-18) 
171,793 0.000406 0.000797 0.001300 0.002440 0.035900  
 Frequent Treatment 
(19-1150) 
166,768 0.000158 0.000477 0.00101 0.001950 0.039700  
Sleep Disorder 
Duration (months) 
No Exposure (0) 608,374 0.000199 0.000416 0.000740 0.001340 0.022600 0.0891 
 Mild Exposure (1-
26) 
  18,755 0.000108 0.000329 0.000557 0.001210 0.113700  
 Moderate Exposure 
(27-62) 
  18,158 0 0.000223 0.000395 0.000947 0.018900  
 Severe Exposure 
(63-149) 







Covariate N 3-year 5-year 7-year 10-year 12.5 year p-Value 
Age (years) at Study 
Entry 
18-34 102,501 0 0 0 0 0.000178 <0.0001 
 35-44 118,952 0 0.000110 0.000179 0.000361 0.035900  
 45-54 174,996 0.000115 0.000268 0.000537 0.001250 0.033100  
 55-64 104,475 0.000264 0.000567 0.000946 0.001810 0.017900  
 ≥ 65 162,945 0.000469 0.000929 0.001700 0.002870 0.026100  
State of Residence SC 175,517 0.000186 0.000451 0.000911 0.001630 0.027400 <0.0001 
 GA 237,107 0.000245 0.000489 0.000744 0.001390 0.035100  
 AL 156,268 0.000176 0.000367 0.000696 0.001250 0.016800  
 Other    94,977 0.000053 0.000117 0.000250 0.000492 0.006190  
Race European American 298,339 0.000195 0.000468 0.000859 0.001640 0.019100 <0.0001 
 African-American 173,942 0.000345 0.000628 0.001090 0.001810 0.070700  
 Other/Unknown 191,588 0.000027 0.000075 0.000115 0.000273 0.004670  
Sex Male 583,454 0.000210 0.000442 0.000793 0.001460 0.025400 <0.0001 
 Female   71,610 0.000014 0.000085 0.000099 0.001860 0.008730  
 Unknown     8,805 0 0 0 0.000115 0.015100  
Diabetes No 626,109 0.000182 0.000385 0.000680 0.001230 0.024600 <0.0001 
 Yes   37,760 0.000243 0.000583 0.001100 0.002250 0.023000  
Mental Disorder/ 
Mental  Retardation 
No 555,499 0.000192 0.000383 0.000654 0.001170 0.017700 <0.0001 




No 444,622 0.000146 0.000313 0.000536 0.000962 0.023700 <0.0001 







Covariate N 3-year 5-year 7-year 10-year 12.5 year p-Value 
Marital Status Married  342,114 0.000152 0.000349 0.000675 0.001240 0.015500 <0.0001 
 Single    51,846 0.000176 0.000336 0.000706 0.001130 0.026500  
 Divorced  118,148 0.000258 0.000543 0.000856 0.001640 0.029300  
 Widowed    45,455 0.000455 0.000825 0.001490 0.002870 0.039100  
 Unknown 106,306 0.000104 0.000240 0.000319 0.000573 0.048100  
1
Other sleep disorders includes: hypersomnia, parasomnia, circadian rhythm, movement disorders, and arousal disorders. 









Table 4.6: Results of Kaplan Meier Survival Analysis: PROSTATE CANCER, for Veterans in the SE USA (VISN-7, 1999-2010). 
Covariate N 3-year 5-year 7-year 10-year 12.5 year p-Value 
Sleep Disorders         
All  No 531,651 0.002930 0.005280 0.007640 0.011900 0.014900 <0.0001 
 Yes   51,803 0.000426 0.001510 0.002910 0.007360 0.010800  
Apneas No 559,410 0.002810 0.005100 0.007420 0.011700 0.014700 <0.0001 
 Yes   24,044 0.000334 0.001350 0.002550 0.007340 0.010700  
Insomnias No 563,042 0.002780 0.005060 0.007370 0.011600 0.014700 <0.0001 
 Yes   20,412 0.000492 0.001540 0.002970 0.007390 0.010600  
Other
1
 No 576,107 0.002730 0.004980 0.007250 0.011500 0.014600 0.0331 
 Yes     7,347 0.000549 0.001940 0.003940 0.007350 0.011800  
Cumulative Sleep 
Disorder Treatment  
No Treatment (0) 226,648 0.003920 0.006350 0.008590 0.011600 0.013600 <0.0001 
 Mild Treatment (1)   46,377 0.003030 0.005530 0.008210 0.013400 0.017700  
 Moderate Treatment 
(2-18) 
156,432 0.002750 0.005370 0.007800 0.013400 0.017400  
 Frequent Treatment 
(19-1150) 
153,997 0.000782 0.002260 0.004300 0.008870 0.012500  
Sleep Disorder 
Duration (months) 
None (0) 532,165 0.002920 
 
0.005270 0.007640 0.011900 0.014900 <0.0001 
 Mild (1-26)    17,120 0.001120 0.002880 0.005190 0.012000 0.015800  
 Moderate (27-62)    16,746 0.000179 0.001750 0.003120 0.007180 0.010800  
 Severe (63-149)    17,423 0 0 0.000576 0.003230 0.006170  
Age (years) at Study 
Entry 
18-34    72,147 0 0 0.000014 0.000056 0.000267 <0.0001 







Covariate N 3-year 5-year 7-year 10-year 12.5 year p-Value 
 45-54   160,173 0.001400 0.003290 0.006010 0.012900 0.018400  
 55-64     98,684 0.004450 0.009280 0.013700 0.021000 0.025200  
 ≥ 65   156,937 0.005800 0.009100 0.011900 0.014900 0.016200  
State of Residence SC   159,255 0.003270 0.006510 0.009810 0.015300 0.019700 <0.0001 
 GA   207,473 0.002970 0.005230 0.007390 0.012300 0.016300  
 AL 139,979 0.002290 0.00395 0.00593 0.00925 0.01090  
 Other    76,747 0.001560 0.00271 0.00375 0.00551 0.00608  
Race European American 279,199 0.002590 0.00467 0.00669 0.01020 0.01260 <0.0001 
 African-American 150,732 0.004740 0.00857 0.01260 0.02060 0.02660  
 Other/Unknown 153,523 0.000909 0.00185 0.00282 0.00452 0.00572  
Diabetes No 547,476 0.002610 0.00475 0.00696 0.01110 0.01410 <0.0001 
 Yes   35,978 0.004090 0.00784 0.01100 0.01690 0.02150  
Mental Disorder/ 
Mental  Retardation 
No 485,414 0.002510 0.00462 0.00667 0.01050 0.01340 <0.0001 





No 376,738 0.002130 0.00391 0.00570 0.00931 0.01190 <0.0001 
 Yes 206,716 0.003760 0.00683 0.01000 0.01560 0.01970  
Marital Status Married  323,299 0.002680 0.00483 0.00698 0.01110 0.01380 <0.0001 
 Single    43,186 0.001910 0.00358 0.00552 0.00969 0.01210  
 Divorced  105,018 0.002710 0.00548 0.00829 0.01400 0.01860  
 Widowed   42,575 0.005640 0.00976 0.01380 0.01990 0.02370  







Covariate N 3-year 5-year 7-year 10-year 12.5 year p-Value 
1
Other sleep disorders includes: hypersomnia, parasomnia, circadian rhythm, movement disorders, and arousal disorders. 








Table 4.7: Results of Kaplan Meier Survival Analysis: FEMALE BREAST CANCER, for Veterans in the SE USA (VISN-7, 1999-
2010). 
Covariate N 3-year 5-year 7-year 10-year 12.5 year p-Value 
Sleep Disorders         
All  No 67,810 0.000517 0.000935 0.001330 0.001950 0.002480 0.8232 
 Yes   3,800 0.000263 0.000263 0.001060 0.001870 0.002690  
Apneas No 70,288 0.000499 0.000902 0.001290 0.001930 0.002480 0.6766 
 Yes   1,322 0.000756 0.000756 0.002280 0.003050 0.003050  
Insomnias No 69,809 0.000517 0.000922 0.001330 0.001970 0.002480 0.7813 
 Yes   1,801 0 0 0.000559 0.001130 0.002870  
Cumulative Sleep 
Disorder Treatment  
No Treatment (0) 40,459 0.000470 0.000720 0.000896 0.001150 0.001390 <0.0001 
 Mild Treatment (1)   4,954 0.000808 0.001010 0.001010 0.001840   
 Moderate 
Treatment (2-18) 
13,896 0.000795 0.001520 0.002260 0.003380 0.004130  
 Frequent Treatment 
(19-1150) 
12,301 0.000163 0.000740 0.001740 0.003010 0.004500  
Sleep Disorder 
Duration 
None (0) 67,851 0.000517 0.000934 0.001330 0.001950 0.002480 0.2884 
 Mild (1)   1,296 0.000772 0.000772 0.002340 0.003140   
 Moderate (2-18)   1,310 0 0 0.000771 0.002330 0.002330  
 Severe (19-1150)   1,153 0 0 0 0 0.000906  
Age (years) at Study 
Entry  
18-34 27,340 0.000037 0.000073 0.000220 0.000514 0.000846 <0.0001 
 35-44 21,329 0.000469 0.000987 0.001510 0.002510 0.003420  







Covariate N 3-year 5-year 7-year 10-year 12.5 year p-Value 
 55-64   4,898 0.001230 0.001440 0.001870 0.002090 0.002310  
 ≥ 65   5,215 0.001170 0.002210 0.002440 0.002960 0.002960  
State of Residence SC 16,179 0.000743 0.001240 0.001620 0.002460 0.003180 0.0106 
 GA 29,445 0.000613 0.000956 0.001370 0.001970 0.002720  
 AL 16,112 0.000311 0.000813 0.001320 0.001900 0.002230  
 Other    9,874 0.000101 0.000305 0.000613 0.001130 0.001130  
Race European American 15,610 0.001220 0.002330 0.002860 0.004090 0.004930 <0.0001 
 African-American 20,994 0.000811 0.001290 0.002110 0.003080 0.004210  
 Other/Unknown 35,006 0 0.000029 0.000145 0.000323 0.000383  
Diabetes No 70,065 0.000486 0.000876 0.001240 0.001800 0.002360 <0.0001 
 Yes   1,545 0.001310 0.001970 0.004670 0.008860   
Mental Disorder/ 
Mental  Retardation 
No 62,206 0.000419 0.000727 0.001140 0.001700 0.002190 <0.0001 




No 60,567 0.000364 0.000564 0.000816 0.001210 0.001520 <0.0001 
 Yes 10,769 0.001270 0.002750 0.004070 0.006090 0.007970  
Marital Status Married  18,799 0.000479 0.001020 0.001400 0.002000 0.002510 <0.0001 
 Single    8,659 0.000579 0.001040 0.001280 0.002230 0.002950  
 Divorced  13,129 0.000840 0.001450 0.002380 0.003790 0.005070  
 Widowed    2,878 0.002460 0.004290 0.005060 0.006320 0.006320  
 Unknown 28,145 0.000142 0.000178 0.000395 0.000540 0.000763  
1
Other sleep disorders includes: hypersomnia, parasomnia, circadian rhythm, movement disorders, and arousal disorders. 







Table 4.8: Results of Kaplan Meier Survival Analysis: ALL OTHER CANCER, for Veterans in the SE USA (VISN-7, 1999-2010). 
Covariate N 3-year 5-year 7-year 10-year 12.5 year p-Value 
Sleep Disorders:         
All  No 607,814 0.003050 0.005220 0.007730 0.011500 0.014200 <0.0001 
 Yes   56,055 0.000644 0.001570 0.003050 0.006670 0.010100  
Apneas No 638,267 0.002930 0.005050 0.007040 0.011200 0.014100 <0.0001 
 Yes    25,602 0.000626 0.001380 0.002660 0.006160 0.009220  
Insomnias No 641,489 0.002930 0.005020 0.007000 0.022300 0.014000 <0.0001 
 Yes   22,380 0.000405 0.001490 0.003210 0.006770 0.011000  
Other
1
 No 655,796 0.002860 0.004930 0.006910 0.011100 0.013900 0.0163 
 Yes     8,073 0.001370 0.002390 0.003820 0.008000 0.010800  
Cumulative Sleep 
Disorder Treatment  
No Treatment (0) 273,450 0.002980 0.004580 0.005940 0.008530 0.009900 <0.0001 
 Mild Treatment (1)   51,858 0.004010 0.006490 0.008380 0.012900 0.015600  
 Moderate 
Treatment (2-18) 
171,793 0.003610 0.006290 0.008880 0.014100 0.017700  
 Frequent Treatment 
(19-1150) 
166,768 0.001480 0.003540 0.005900 0.011500 0.016300  
Sleep Disorder Duration None (0) 608,374 0.003050 0.005220 0.007240 0.011500 0.014200 <0.0001 
 Mild (1-26)   18,755 0.001560 0.003330 0.005320 0.010300 0.014500  
 Moderate (27-62)    18,158 0.000220 0.001770 0.002940 0.006760 0.009500  
 Severe (63-149)   18,582 0 0 0.000594 0.002710 0.006010  
Age (years) at Study 
Entry 
18-34 102,501 0.000146 0.000205 0.000283 0.000460 0.000796 <0.0001 
 35-44 118,952 0.000430 0.001300 0.001710 0.003420 0.005250  







Covariate N 3-year 5-year 7-year 10-year 12.5 year p-Value 
 55-64 104,475 0.004940 0.008810 0.012500 0.019000 0.023200  
 ≥ 65 162,945 0.005830 0.009340 0.012500 0.018400 0.020800  
State of Residence SC 175,517 0.003290 0.005760 0.008110 0.012900 0.016500 <0.0001 
 GA 237,107 0.003320 0.005550 0.007380 0.012200 0.015900  
 AL 156,268 0.002700 0.004800 0.007300 0.011500 0.013700  
 Other    94,977 0.001090 0.001920 0.002720 0.004300 0.004880  
Race European American 298,339 0.004160 0.007150 0.010000 0.015900 0.020000 <0.0001 
 African-American 173,942 0.003060 0.005200 0.007280 0.012000 0.015300  
 Other/Unknown 191,588 0.000606 0.001160 0.001610 0.002650 0.003240  
Sex Male 583,454 0.003190 0.005490 0.007720 0.012400 0.015700 <0.0001 
 Female   71,610 0.000350 0.000745 0.001000 0.001670 0.002290  
 Unknown     8,805 0.000228 0.000456 0.000685 0.000916 0.000916  
Diabetes No 626,109 0.002800 0.004820 0.006730 0.010800 0.013600 <0.0001 
 Yes   37,760 0.003600 0.006280 0.009190 0.015200 0.019200  
Mental Disorder/ Mental  
Retardation 
No 555,499 0.002520 0.004300 0.005990 0.009520 0.012000 <0.0001 
 Yes 108,370 0.004500 0.007980 0.011400 0.018800 0.023300  
Cardiovascular Disease, 
Hypertension, and Stroke 
No 444,622 0.002340 0.004010 0.005540 0.008810 0.011000 <0.0001 
 Yes 219,247 0.003870 0.006740 0.009640 0.015800 0.020100  
Marital Status Married  342,114 0.002720 0.004650 0.006570 0.010300 0.012900 <0.0001 
 Single    51,846 0.002610 0.004260 0.006090 0.010100 0.012300  
 Divorced  118,148 0.003630 0.006520 0.009100 0.015500 0.019900  
 Widowed    45,455 0.005240 0.009210 0.012800 0.021000 0.026400  







Covariate N 3-year 5-year 7-year 10-year 12.5 year p-Value 
1
Other sleep disorders includes: hypersomnia, parasomnia, circadian rhythm, movement disorders, and arousal disorders. 







































Table 4.9:  Sleep Disorder Diagnoses and Cancer Incidence Among Veterans in the SE USA (VISN-7, 1999-2010). 
Cancer Site Sleep Disorder Type Crude Adjusted
3
 
Hazard Ratio 95% CI Hazard Ratio 95% CI 
All  All 1.75 (1.66, 1.86) 1.45 (1.37, 1.54) 
Prostate All 1.73 (1.58, 1.90) 1.50 (1.37, 1.64) 
Colon  All 1.52 (1.32, 1.75) 1.34 (1.16, 1.54) 
Female Breast  All 2.87 (1.50, 5.49) 1.69 (0.88, 3.24) 
Other
1
 All 1.75 (1.60, 1.91) 1.45 (1.33, 1.59) 
All Insomnias 1.73 (1.58, 1.89) 1.39 (1.27, 1.52) 
Prostate Insomnias 1.64 (1.43, 1.90) 1.39 (1.20, 1.60) 
Colon Insomnias 1.46 (1.17, 1.82) 1.22 (0.98, 1.51) 
Female Breast  Insomnias 2.98 (1.21, 7.30) 1.78 (0.73, 4.38) 
Other
1
 Insomnias 1.84 (1.61, 2.10) 1.46 (1.28, 1.67) 
All Apneas 1.70 (1.55, 1.84) 1.44 (1.32, 1.57) 
Prostate  Apneas 1.72 (1.51, 1.96) 1.52 (1.38, 1.73) 
Colon Apneas 1.48 (1.21, 1.81) 1.38 (1.12, 1.69) 
Female Breast  Apneas 3.31 (1.22, 8.99) 1.90 (0.69, 5.17) 
Other
1
 Apneas 1.59 (1.39, 1.82) 1.37 (1.20, 1.57) 
All Other
2
 1.68 (1.46, 1.94) 1.47 (1.28, 1.70) 
Prostate Other
2
 1.69 (1.35, 2.11) 1.54 (1.23, 1.92) 
Colon  Other
2





 1.68 (1.35, 2.09) 1.47 (1.18, 1.83) 
1
Other Cancer includes: Lung, pancreatic, kidney, brain, bladder, liver, ovarian, esophageal, gastric, and melanoma cancers. 
2
Other 
sleep disorders include: hypersomnia, parasomnia, circadian rhythm, movement disorders, and arousal disorders. 
3
Adjusted for marital 







Table 4.10:  Cumulative Sleep Disorder Treatments and Cancer Incidence Among Veterans in the SE USA (VISN-7, 1999-2010). 















Treatment -- 0.96 (0.96, 0.97) 0.96 (0.95, 0.96) 
Treatment*Time 1 1.01 (1.01, 1.01) 1.01 (1.01, 1.01) 
25  1.22 (1.20, 1.24) 1.26 (1.24, 1.28) 
50  1.49 (1.45, 1.53) 1.60 (1.54, 1.65) 
100  2.22 (2.09, 2.35) 2.55 (2.38, 2.72) 
Prostate  Treatment -- 0.95 (0.95, 0.96) 0.94 (0.94, 0.95) 
 
Treatment*Time 
1 1.01 (1.01, 1.01) 1.01 (1.01, 1.01) 
25  1.31 (1.27, 1.35) 1.35 (1.30, 1.39) 
50  1.71 (1.61, 1.81) 1.81 (1.70, 1.93) 
100  2.91 (2.58, 3.29) 3.28 (2.88, 3.74) 
Colon  Treatment -- 0.99 (0.98, 0.99) 0.98 (0.97, 0.99) 
 
Treatment*Time 
1 1.004 (1.002, 1.005) 1.004 (1.002, 1.006) 
25  1.10 (1.06, 1.14) 1.10 (1.06, 1.15) 
50  1.21 (1.11, 1.30) 1.22 (1.12, 1.33) 
100  1.45 (1.24, 1.70) 1.49 (1.25, 1.77) 
Female Breast  Treatment -- 0.99 (0.97, 1.00) 0.97 (0.95, 0.99) 
 
Treatment*Time 
1 1.00 (1.00, 1.01) 1.006 (1.001, 1.01) 
25  1.10 (0.99, 1.23) 1.17 (1.02, 1.34) 
50  1.22 (0.98, 1.51) 1.36 (1.04, 1.78) 
100  1.49 (0.97, 2.29) 1.85 (1.08, 2.18) 
Other
1
 Treatment -- 0.97 (0.96, 0.97) 0.96 (0.96, 0.97) 
 
Treatment*Time 
1 1.007 (1.007, 1.008) 1.01 (1.01, 1.01) 
25  1.20 (1.18, 1.23) 1.24 (1.22, 1.27) 
50  1.45 (1.39, 1.51) 1.54 (1.48, 1.61) 
100  2.09 (1.93, 2.27) 2.38 (2.18, 2.60) 
Treatment includes a sum of sleep disorder prescriptions, procedures, and surgeries. 
1









liver, ovarian, esophageal, gastric cancers, and melanoma.  Cumulative sum of sleep disorder prescriptions, procedures, and surgeries. 
3










Table 4.11:  Sleep Disorder Duration and Cancer Incidence Among Veterans in the SE USA (VISN-7, 1999-2010). 





95% CI Hazard Ratio 95% CI 
All  1  1.08 (1.07, 1.10) 1.04 (1.03, 1.06) 
5  1.48 (1.39, 1.58) 1.23 (1.16, 1.32) 
10  2.20 (1.94, 2.50) 1.52 (1.34, 1.73) 
Prostate  1  1.07 (1.05, 1.10) 1.04 (1.02, 1.07) 
5  1.43 (1.28, 1.59) 1.24 (1.11, 1.38) 
10  2.04 (1.65, 2.53) 1.53 (1.24, 1.90) 
Colon  1  1.08 (1.06, 1.11) 1.05 (1.03, 1.08) 
5  1.48 (1.31, 1.67) 1.29 (1.14, 1.46) 
10  2.18 (1.70, 2.79) 1.65 (1.29, 2.12) 
Female Breast  1  1.13 (0.96, 1.33) 1.03 (0.87, 1.23) 
5  1.86 (0.82, 4.23) 1.17 (0.49, 2.80) 
10 3.46 (0.67, 17.85) 1.38 (0.24, 7.83) 
Other
2
 1  1.08 (1.05, 1.10) 1.04 (1.01, 1.06) 
5 1.45 (1.30, 1.61) 1.20 (1.07, 1.33) 
10 2.10 (1.70, 2.59) 1.43 (1.15, 1.77) 
1
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
2 
Includes: lung, pancreatic, kidney, 









Table 4.12:  All Sleep Disorder Diagnosis and Cancer Incidence Stratified by Race Among Veterans in the SE USA (VISN-7, 1999-
2010). 
Cancer Site Sleep Disorder Type Race Stratification N Hazard Ratio 95% CI 
All  All 
 
African-American 173,942 1.28 (1.16, 1.41) 
European American 298,339 1.37 (1.27, 1.48) 
Unknown/Other 191,588 1.76 (1.41, 2.20) 
Prostate  All African-American 150,732 1.46 (1.29, 1.67) 
European American 279,199 1.33 (1.15, 1.53) 
Unknown/Other 153,523 2.03 (1.52, 2.73) 
Colon  All African-American 173,942 1.04 (0.81, 1.33) 
European American 298,339 1.35 (1.23, 1.61) 
Unknown/Other 191,588 1.21 (0.59, 2.48) 
Female Breast  All African-American 20,994 1.03 (0.37, 2.86) 
European American 15,610 1.31 (0.47, 3.67) 
Unknown/Other 35,006 7.75 (1.64, 36.56) 
Other
1
 All African-American 173,942 1.15 (0.96, 1.37) 
European American 298,339 1.39 (1.25, 1.54) 
Unknown/Other 191,588 1.52 (1.01, 2.28) 
Adjusted for: marital status, state or residence, gender (except for gender specific cancers), and age. 
1 
Includes: lung, pancreatic, 

















Table 4.13:  Insomnia Sleep Disorder Diagnosis and Cancer Incidence Stratified by Race Among Veterans in the SE USA (VISN-7, 
1999-2010). 
Cancer Site Sleep Disorder Type Race Stratification N Hazard Ratio 95% CI 
All  Insomnias African-American 173,942 1.33 (1.15, 1.53) 
European American 298,339 1.27 (1.13, 1.43) 
Unknown/Other 191,588 1.65 (1. 18, 2.30) 
Prostate Insomnias African-American 150,732 1.44 (1.18, 1.76) 
European American 279,199 1.12 (0.88, 1.42) 
Unknown/Other 153,523 2.06 (1.36, 3.14) 
Colon  Insomnias African-American 173,942 1.21 (0.85, 1.72) 
European American 298,339 1.14 (0.86, 1.51) 
Unknown/Other 191,588 0.34 (0.05, 2.41) 
Female Breast  Insomnias African-American 20,994 0.57 (0.08, 4.13) 
European American 15,610 2.01 (0.62, 6.48) 
Unknown/Other 35,006 6.95 (0.87, 55.39) 
Other
1
 Insomnias African-American 173,942 1.24 (0.95, 1.62) 
European American 298,339 1.40 (1.19, 1.64) 
Unknown/Other 191,588 1.47 (0.81, 2.68) 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
1
Includes: lung, pancreatic, kidney, 









Table 4.14:  Apnea Sleep Disorder Diagnosis and Cancer Incidence stratified by Race Among Veterans in the SE USA (VISN-7, 
1999-2010). 
Cancer Site Sleep Disorder Type Race Stratification N Hazard Ratio 95% CI 
All Apneas African-American 173,942 1.16 (1.00, 1.35) 
European American 298,339 1.41 (1.27, 1.57) 
Unknown/Other 191,588 1.80 (1.29, 2.51) 
Prostate Apneas African-American 150,732 1.40 (1.16, 1.69) 
European American 279,199 1.45 (1.19, 1.77) 
Unknown/Other 153,523 1.97 (1.26, 3.08) 
Colon Apneas African-American 173,942 0.85 (0.57, 1.26) 
European American 298,339 1.50 (1.17, 1.91) 
Unknown/Other 191,588 1.41 (0.52, 3.84) 
Female Breast Apneas African-American 20,994 1.41 (0.34, 5.78) 
European American 15,610 0.98 (0.14, 7.14) 
Unknown/Other 35,006 10.42 (1.29, 84.09) 
Other
1
 Apneas African-American 173,942 0.96 (0.72, 1.29) 
European American 298,339 1.34 (1.14, 1.57) 
Unknown/Other 191,588 1.62 (0.89, 2.95) 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
1
Includes: lung, pancreatic, kidney, 









Table 4.15:  Other Sleep Disorder Diagnosis and Cancer Incidence stratified by Race Among Veterans in the SE USA (VISN-7, 1999-
2010). 
Cancer Site Sleep Disorder Type Race Stratification N Hazard Ratio 95% CI 
All  Other
2
 African-American 173,942 1.39 (1.11, 1.74) 
European American 298,339 1.33 (1.09, 1.61) 
Unknown/Other 191,588 1.73 (0.98, 3.05) 
Prostate  Other
2
 African-American 150,732 1.51 (1.11, 2.06) 
European American 279,199 1.34 (0.97, 1.95) 
Unknown/Other 153,523 1.70 (0.76, 3.80) 
Colon Other
2
 African-American 173,942 1.11 (0.61, 2.02) 
European American 298,339 1.27 (0.81, 2.01) 





 African-American 173,942 1.36 (0.90, 2.06) 
European American 298,339 1.34 (1.03, 1.75) 
Unknown/Other 191,588 1.26 (0.41, 3.93) 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
1
Includes: lung, pancreatic, kidney, 
brain, bladder, liver, ovarian, esophageal, gastric cancers, and melanoma.  
2
 Includes: hypersomnia, parasomnia, circadian rhythm, 








Table 4.16:  All Sleep Disorder Diagnosis and Cancer Incidence Stratified by the Co-morbid Diabetes Among Veterans in the SE 
USA (VISN-7, 1999-2010). 
Cancer Site  Sleep Disorder Type Co-Morbid Condition N Hazard Ratio 95% CI 
All  All No Diabetes 626,109 1.46 (1.37, 1.55) 
Diabetes 37,760 1.44 (1.18, 1.77) 
Prostate  All No Diabetes 547,476 1.54 (1.40, 1.69) 
Diabetes 35,978 1.21 (0.78, 1.61) 
Colon  All No Diabetes 626,109 1.28 (1.10, 1.49) 
Diabetes 37,760 1.94 (1.29, 2.90) 
Female Breast  All No Diabetes 70,065 1.80 (0.94, 3.47) 
Diabetes 1,545 0 (0, 0) 
Other
1
 All No Diabetes 626,109 1.44 (1.31, 1.58) 
Diabetes 37,760 1.55 (1.12, 2.14) 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
1 
Includes: lung, pancreatic, kidney, 








Table 4.17:  Insomnia Sleep Disorder Diagnosis and Cancer Incidence Stratified by Co-morbid Diabetes Among Veterans in the SE 
USA (VISN-7, 1999-2010). 
Cancer Site Sleep Disorder Type Co-Morbid Condition N Hazard Ratio 95% CI 
All Insomnias No Diabetes 626,109 1.41 (1.29, 1.55) 
Diabetes 37,760 1.16 (0.80, 1.67) 
Prostate  Insomnias No Diabetes 547,476 1.41 (1.22, 1.63) 
Diabetes 35,978 1.12 (0.62, 2.04) 
Colon  Insomnias No Diabetes 626,109 1.20 (0.96, 1.52) 
Diabetes 37,760 1.44 (0.71, 2.92) 
Female Breast Insomnias No Diabetes 70,065 1.86 (0.76, 4.59) 
Diabetes 1,545 0 (0, 0) 
Other
1
 Insomnias No Diabetes 626,109 1.49 (1.30, 1.71) 
Diabetes 37,760 1.06 (0.56, 1.98) 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
1
Includes: Lung, pancreatic, kidney, 








Table 4.18:  Apnea Sleep Disorder Diagnosis and Cancer Incidence Stratified by Co-morbid Diabetes Among Veterans in the SE USA 
(VISN-7, 1999-2010). 
Cancer Site Sleep Disorder Type Co-Morbid Condition N Hazard Ratio 95% CI 
All  Apneas No Diabetes 626,109 1.42 (1.30, 1.55) 
Diabetes 37,760 1.66 (1.27, 2.16) 
Prostate Apneas No Diabetes 547,476 1.54 (1.35, 1.77) 
Diabetes 35,978 1.31 (0.83, 2.08) 
Colon  Apneas No Diabetes 626,109 1.28 (1.03, 1.60) 
Diabetes 37,760 2.14 (1.28, 3.58) 
Female Breast  Apneas No Diabetes 70,065 2.07 (0.76, 5.63) 
Diabetes 1,545 0 (0, 0) 
Other
1
 Apneas No Diabetes 626,109 1.34 (1.16, 1.54) 
Diabetes 37,760 1.75 (1.15, 2.67) 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
1 
Includes: lung, pancreatic, kidney, 









Table 4.19:  Other Sleep Disorder Diagnosis and Cancer Incidence Stratified by Co-morbid Diabetes Among Veterans in the SE USA 
(VISN-7, 1999-2010). 
Cancer Site Sleep Disorder Type
2
 Co-Morbid Condition N Hazard Ratio 95% CI 
All  Other No Diabetes 626,109 1.50 (1.29, 1.73) 
Diabetes 37,760 1.24 (0.72, 2.15) 
Prostate  Other No Diabetes 547,476 1.64 (1.31, 2.05) 
Diabetes 35,978 0.46 (0.12, 1.85) 
Colon  Other No Diabetes 626,109 1.36 (0.94, 1.96) 
Diabetes 37,760 1.88 (0.70, 5.07) 
Other
1 
Other No Diabetes 626,109 1.45 (1.15, 1.82) 
Diabetes 37,760 1.83 (0.87, 3.86) 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
1
Includes: lung, pancreatic, kidney, 
brain, bladder, liver, ovarian, esophageal, gastric cancers, and melanoma. 
2
 Includes: hypersomnia, parasomnia, circadian rhythm, 









Table 4.20: All Sleep Disorder Diagnosis and Cancer Incidence Stratified by the Co-morbid Mental Disorders and Mental Retardation  
Among Veterans in the SE USA (VISN-7, 1999-2010). 
Cancer Site Sleep Disorder Type Co-Morbid Condition N Hazard 
Ratio 
95% CI 
All  All No Mental Disorders or Mental Retardation 555,499 1.56 (1.46, 1.67) 
Mental Disorders or Mental Retardation 108,370 1.16 (1.02, 1.31) 
Prostate  All No Mental Disorders or Mental Retardation 485,414 1.54 (1.39, 1.71) 
Mental Disorders or Mental Retardation 98,040 1.38 (1.13, 1.68) 
Colon  All No Mental Disorders or Mental Retardation 555,499 1.53 (1.31, 1.79) 
Mental Disorders or Mental Retardation 108,370 0.84 (0.60, 1.17) 
Female Breast  All No Mental Disorders or Mental Retardation 62,206 1.82 (0.88, 3.78) 
Mental Disorders or Mental Retardation 9,404 1.21 (0.28, 5.16) 
Other 
1
 All No Mental Disorders or Mental Retardation 555,499 1.59 (1.44, 1.76) 
Mental Disorders or Mental Retardation 108,370 1.11 (0.91, 1.35) 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
1
Includes: lung, pancreatic, kidney, 









Table 4.21:  Insomnia Sleep Disorder Diagnosis and Cancer Incidence Stratified by Co-morbid Mental Disorders and Mental 
Retardation Among Veterans in the SE USA (VISN-7, 1999-2010). 
Cancer Site Sleep Disorder 
Type 




All  Insomnias No Mental Disorders or Mental Retardation 555,499 1.47 (1.33, 1.62) 
Mental Disorders or Mental Retardation 108,370 1.14 (0.95, 1.37) 
Prostate  Insomnias No Mental Disorders or Mental Retardation 485,414 1.39 (1.18, 1.64) 
Mental Disorders or Mental Retardation 98,040 1.31 (0.98, 1.76) 
Colon  Insomnias No Mental Disorders or Mental Retardation 555,499 1.32 (1.03, 1.69) 
Mental Disorders or Mental Retardation 108,370 0.92 (0.57, 1.47) 
Female Breast  Insomnias No Mental Disorders or Mental Retardation 62,206 1.92 (0.70, 5.24) 
Mental Disorders or Mental Retardation 9,404 1.23 (0.17, 9.07) 
Other
1
 Insomnias No Mental Disorders or Mental Retardation 555,499 1.59 (1.37, 1.85) 
Mental Disorders or Mental Retardation 108,370 1.10 (0.83, 1.46) 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
1
Includes: lung, pancreatic, kidney, 









Table 4.22:  Apnea Sleep Disorder Diagnosis and Cancer Incidence Stratified by Co-morbid Mental Disorders and Mental Retardation  
Among Veterans in the SE USA (VISN-7, 1999-2010). 
Cancer Site  Sleep Disorder 
Type 
Co-Morbid Condition N Hazard 
Ratio 
95% CI 
All  Apneas No Mental Disorders or Mental Retardation 555,499 1.55 (1.417, 1.71) 
Mental Disorders or Mental Retardation 108,370 1.15 (0.94, 1.40) 
Prostate Apneas No Mental Disorders or Mental Retardation 485,414 1.57 (1.36, 1.82) 
Mental Disorders or Mental Retardation 98,040 1.40 (1.04, 1.88) 
Colon  Apneas No Mental Disorders or Mental Retardation 555,499 1.64 (1.32, 2.04) 
Mental Disorders or Mental Retardation 108,370 0.63 (0.35, 1.14) 
Female Breast  Apneas No Mental Disorders or Mental Retardation 62,206 2.57 (0.94, 7.04) 
Mental Disorders or Mental Retardation 9,404 0 (0,0) 
Other
1 
Apneas No Mental Disorders or Mental Retardation 555,499 1.47 (1.27, 1.71) 
Mental Disorders or Mental Retardation 108,370 1.17 (0.87, 1.57) 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age.
1
Includes: lung, pancreatic, kidney, 






   
Table 4.23:  Other Sleep Disorder Diagnosis and Cancer Incidence Stratified by Co-morbid Mental Disorders and Mental Retardation 
Among Veterans in the SE USA (VISN-7, 1999-2010). 




Co-Morbid Condition N Hazard 
Ratio 
95% CI 
All  Other No Mental Disorders or Mental Retardation 555,499 1.58 (1.35, 1.85) 
Mental Disorders or Mental Retardation 108,370 1.18 (0.86, 1.61) 
Prostate  Other No Mental Disorders or Mental Retardation 485,414 1.59 (1.24, 2.04) 
Mental Disorders or Mental Retardation 98,040 1.37 (0.84, 2.25) 
Colon  Other No Mental Disorders or Mental Retardation 555,499 1.47 (0.99, 2.18) 
Mental Disorders or Mental Retardation 108,370 1.22 (0.61, 2.45) 
Other
1
 Other No Mental Disorders or Mental Retardation 555,499 1.67 (1.31, 2.12) 
Mental Disorders or Mental Retardation 108,370 0.96 (0.56, 1.63) 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
1
Includes: lung, pancreatic, kidney, 
brain, bladder, liver, ovarian, esophageal, gastric cancers, and melanoma. 
2 
Includes: hypersomnia, parasomnia, circadian rhythm, 









Table 4.24:  All Sleep Disorder Diagnosis and Cancer Incidence Stratified by the Co-morbid Conditions of Hypertension, Stroke,  
and/or Cardiovascular Disease Among Veterans in the SE USA (VISN-7, 1999-2010). 
Cancer Site  Sleep Disorder 
Type 




All  All No Hypertension, Cardiovascular Disease, and Stroke 444,622 1.58 (1.47, 1.70) 
Hypertension, Cardiovascular Disease, and Stroke 219,247 1.32 (1.20, 1.45) 
Prostate  All No Hypertension, Cardiovascular Disease, and Stroke 376,738 1.61 (1.44, 1.81) 
Hypertension, Cardiovascular Disease, and Stroke 206,716 1.39 (1.19, 1.62) 
Colon  All No Hypertension, Cardiovascular Disease, and Stroke 444,622 1.37 (1.14, 1.66) 
Hypertension, Cardiovascular Disease, and Stroke 219,247 1.36 (1.10, 1.70) 
Female Breast  All No Hypertension, Cardiovascular Disease, and Stroke 60,567 3.03 (1.48, 6.18) 
Hypertension, Cardiovascular Disease, and Stroke 11,043 0.35 (0.05,2.51) 
Other
1
 All No Hypertension, Cardiovascular Disease, and Stroke 444,622 1.60 (1.43, 1.79) 
Hypertension, Cardiovascular Disease, and Stroke 219,247 1.27 (1.09, 1.48) 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
1
Includes: Lung, pancreatic, kidney, 







   
Table 4.25:  Insomnia Sleep Disorder Diagnosis and Cancer Incidence Stratified by Co-morbid Conditions of Hypertension, Stroke,  
and/or Cardiovascular Disease Among Veterans in the SE USA (VISN-7, 1999-2010). 
Cancer Site Sleep 
Disorder 
Type 
Co-Morbid Condition N Hazard 
Ratio 
95% CI 
All  Insomnias No Hypertension, Cardiovascular Disease, and Stroke 444,622 1.54 (1.39, 1.72) 
Hypertension, Cardiovascular Disease, and Stroke 219,247 1.21 (1.03, 1.41) 
Prostate  Insomnias No Hypertension, Cardiovascular Disease, and Stroke 376,738 1.56 (1.31, 1.85) 
Hypertension, Cardiovascular Disease, and Stroke 206,716 1.15 (0.88, 1.50) 
Colon Insomnias No Hypertension, Cardiovascular Disease, and Stroke 444,622 1.25 (0.94, 1.66) 
Hypertension, Cardiovascular Disease, and Stroke 219,247 1.25 (0.88, 1.77) 
Female Breast  Insomnias No Hypertension, Cardiovascular Disease, and Stroke 60,567 3.40 (1.35, 8.55) 
Hypertension, Cardiovascular Disease, and Stroke 11,043 0 (0, 0) 
Other
1
 Insomnias No Hypertension, Cardiovascular Disease, and Stroke 444,622 1.62 (1.38, 1.91) 
Hypertension, Cardiovascular Disease, and Stroke 219,247 1.27 (1.00, 1.61) 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
1
Includes: lung, pancreatic, kidney, 









Table 4.26:  Apnea Sleep Disorder Diagnosis and Cancer Incidence Stratified by Co-morbid Conditions of Hypertension, Stroke,  
and/or Cardiovascular Disease Among Veterans in the SE USA (VISN-7, 1999-2010). 
Cancer Site Sleep Disorder 
Type 
Co-Morbid Condition N Hazard 
Ratio 
95% CI 
All Apneas No Hypertension, Cardiovascular Disease, and Stroke 444,622 1.49 (1.34, 1.66) 
Hypertension, Cardiovascular Disease, and Stroke 219,247 1.40 (1.22, 1.60) 
Prostate Apneas No Hypertension, Cardiovascular Disease, and Stroke 376,738 1.51 (1.28, 1.78) 
Hypertension, Cardiovascular Disease, and Stroke 206,716 1.59 (1.29, 1.95) 
Colon Apneas No Hypertension, Cardiovascular Disease, and Stroke 444,622 1.33 (1.01, 1.75) 
Hypertension, Cardiovascular Disease, and Stroke 219,247 1.50 (1.11, 2.02) 
Female Breast Apneas No Hypertension, Cardiovascular Disease, and Stroke 60,567 2.77 (0.86, 9.92) 
Hypertension, Cardiovascular Disease, and Stroke 11,043 0.93 (0.13, 6.70) 
Other
1
 Apneas No Hypertension, Cardiovascular Disease, and Stroke 444,622 1.51 (1.28, 1.78) 
Hypertension, Cardiovascular Disease, and Stroke 219,247 1.20 (0.95, 1.51) 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
1
Includes: lung, pancreatic, kidney, 







Table 4.27:  Other Sleep Disorder Diagnosis and Cancer Incidence Stratified by Co-morbid Conditions of Hypertension, Stroke,  
and/or Cardiovascular Disease Among Veterans in the SE USA (VISN-7, 1999-2010). 




Co-Morbid Condition N Hazard 
Ratio 
95% CI 
All  Other No Hypertension, Cardiovascular Disease, and 
Stroke 
444,622 1.64 (1.38, 1.95) 
Hypertension, Cardiovascular Disease, and 
Stroke 
219,247 1.28 (0.99, 1.63) 
Prostate  Other No Hypertension, Cardiovascular Disease, and 
Stroke 
376,738 1.75 (1.34, 2.29) 
Hypertension, Cardiovascular Disease, and 
Stroke 
206,716 1.29 (0.82, 1.86) 
Colon Other No Hypertension, Cardiovascular Disease, and 
Stroke 
444,622 1.66 (1.09, 2.53) 
Hypertension, Cardiovascular Disease, and 
Stroke 
219,247 1.13 (0.62, 2.04) 
Other
1
 Other No Hypertension, Cardiovascular Disease, and 
Stroke 
444,622 1.54 (1.17, 2.03) 
Hypertension, Cardiovascular Disease, and 
Stroke 
219,247 1.41 (0.99, 2.03) 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
1
Includes: lung, pancreatic, 
kidney, brain, bladder, liver, ovarian, esophageal, gastric cancers, and melanoma. 
2
 Includes: hypersomnia, parasomnia, circadian 







Table 4.28:  Duration of Sleep Disorder Diagnosis and Cancer Incidence Stratified by Race Among Veterans in the SE USA (VISN-7, 
1999-2010). 




 Hazard Ratio 95% CI 
All  1  European American 298,339 1.00 (1.00, 1.01) 
African-American 173,942 1.00 (1.00, 1.01) 
Other/Unknown 191,588 1.00 (1.00, 1.01) 
5  European American  1.17 (1.08, 1.28) 
African-American 1.12 (1.01, 1.25) 
Other/Unknown 1.30 (0.99, 1.71) 
10 European American 1.38 (1.16, 1.64) 
African-American 1.26 (1.02, 1.56) 
Other/Unknown 1.69 (0.98, 2.93) 
Prostate 1 European American 279,199 1.00 (0.99, 1.01) 
African-American 150,732 1.00 (1.00, 1.01) 
Other/Unknown 153,523 1.01 (1.00, 1.01) 
5 European American  1.11 (0.93, 1.32) 
African-American 1.19 (1.02, 1.38) 
Other/Unknown 1.66 (1.18, 2.33) 
10 European American 1.23 (0.87, 1.75) 
African-American 1.41 (1.05, 1.90) 
Other/Unknown 2.76 (1.40, 5.45) 
Colon  1 European American 298,339 1.00 (1.00, 1.01) 
African-American 173,942 1.00 (0.99, 1.01) 
Other/Unknown 191,588 0.99 (0.99, 1.01) 
5 European American  1.27 (1.09, 1.49) 
African-American 1.14 (0.91, 1.41) 
Other/Unknown 0.92 (0.42, 2.02) 
10 European American 1.62 (1.18, 2.21) 







Table 4.28:  Duration of Sleep Disorder Diagnosis and Cancer Incidence Stratified by Race Among Veterans in the SE USA (VISN-7, 
1999-2010). 




 Hazard Ratio 95% CI 
Other/Unknown 0.85 (0.18, 4.10) 
Female Breast  1  European American 15,610 0.99 (0.96, 1.02) 
African-American 20,994 1.00 (0.98, 1.02) 
Other/Unknown 35,006 1.02 (0.98, 1.06) 
5 European American  0.52 (0.07, 3.85) 
African-American 1.18 (0.39, 3.59) 
Other/Unknown 3.25 (0.38, 27.76) 
10 European American 0.27 (0.01, 14.82) 
African-American 1.40 (0.15, 12.87) 
Other/Unknown 10.58 (0.15, 770.74) 
Other
2
 1 European American 298,339 1.00 (1.00, 1.01) 
African-American 173,942 1.00 (0.99, 1.00) 
Other/Unknown 191,588 0.99 (0.99, 1.01) 
5 European American  1.15 (1.02, 1.46) 
African-American 1.01 (0.82, 1.25) 
Other/Unknown 0.93 (0.51, 1.70) 
10 European American 1.33 (1.03, 1.72) 
African-American 1.02 (0.67, 1.57) 
Other/Unknown 0.87 (0.26, 2.89) 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
1
N presented are for the main effect. 
2
 










Table 4.29: Cumulative Sleep Disorder Treatment and Cancer Incidence Stratified by race Among Veterans in the SE USA (VISN-7, 
1999-2010). 











Treatment  European American 298,339 0.96 (0.95, 0.96) 
African-American 173,942 0.93 (0.92, 0.94) 
Other/Unknown 191,588 0.94 (0.92, 0.96) 
Treatment* Time 1 European American  1.01 (1.01, 1.01) 
African-American 1.02 (1.01, 1.02) 
Other/Unknown 1.01 (1.01, 1.02) 
25  European American 1.25 (1.22, 1.27) 
African-American 1.44 (1.39, 1.50) 
Other/Unknown 1.41 (1.28, 1.55) 
50  European American 1.56 (1.50, 1.62) 
African-American 2.08 (1.92, 2.25) 
Other/Unknown 1.98 (1.64, 2.39) 
100  European American 2.42 (2.24, 2.62) 
African-American 4.32 (3.68, 5.07) 
Other/Unknown 3.92 (2.70, 5.70) 
Prostate  Treatment  European American 279,199 0.95 (0.94, 0.96) 
African-American 150,732 0.92 (0.91, 0.93) 
Other/Unknown 153,523 0.93 (0.91, 0.96) 
Treatment*Time 1 European American  1.01 (1.01, 1.01) 
African-American 1.02 (1.02, 1.02) 
Other/Unknown 1.02 (1.01, 1.02) 
25 European American 1.31 (1.26, 1.37) 
African-American 1.54 (1.44, 1.64) 
Other/Unknown 1.46 (1.27, 1.68) 
50 European American 1.72 (1.58, 1.87) 







Table 4.29: Cumulative Sleep Disorder Treatment and Cancer Incidence Stratified by race Among Veterans in the SE USA (VISN-7, 
1999-2010). 









Other/Unknown 2.13 (1.61, 2.82) 
100 European American 2.96 (2.51, 3.49) 
African-American 5.56 (4.28, 7.22) 
Other/Unknown 4.54 (2.61, 7.93) 
Colon  Treatment  European American 298,339 0.99 (0.98, 0.99) 
African-American 173,942 0.97 (0.95, 0.99) 
Other/Unknown 191,588 0.98 (0.93, 1.03) 
Treatment*Time 1 European American  1.00 (1.00, 1.01) 
African-American 1.01 (1.00, 1.01) 
Other/Unknown 1.01 (0.99, 1.02) 
25 European American 1.09 (1.04, 1.15) 
African-American 1.20 (1.08, 1.34) 
Other/Unknown 1.13 (0.86, 1.49) 
50 European American 1.19 (1.07, 1.32) 
African-American 1.44 (1.16, 1.78) 
Other/Unknown 1.28 (0.74, 2.22) 
100 European American 1.41 (1.15, 1.73) 
African-American 2.07 (1.34, 3.18) 
Other/Unknown 1.65 (0.55, 4.92) 
Female Breast  Treatment  European American 15,610 0.96 (0.93, 1.00)  
African-American 20,994 0.96 (0.92, 1.00) 
Other/Unknown 35,006 0.92 (0.65, 1.29) 
Treatment*Time 1 European American  1.01 (0.99, 1.02) 
African-American 1.01 (1.00, 1.02) 
Other/Unknown 1.02 (0.95, 1.10) 







Table 4.29: Cumulative Sleep Disorder Treatment and Cancer Incidence Stratified by race Among Veterans in the SE USA (VISN-7, 
1999-2010). 









African-American 1.24 (0.99, 1.56) 
Other/Unknown 1.58 (0.26, 9.67) 
50 European American 1.46 (0.97, 2.20) 
African-American 1.55 (0.99, 2.42) 
Other/Unknown 2.50 (0.07, 93.49) 
100 European American 2.13 (0.94, 4.83) 
African-American 2.40 (0.98, 5.85) 
Other/Unknown 6.23 (0.01, 8,739.77) 
Other
2
 Treatment  European American 298,339 0.96 (0.95, 0.97) 
African-American 173,942 0.94 (0.93, 0.95) 
Other/Unknown 191,588 0.94 (0.91, 0.96) 
Treatment*Time 1 European American  1.01 (1.00, 1.01) 
African-American 1.01 (1.01, 1.02) 
Other/Unknown 1.01 (1.01, 1.02) 
25 European American 1.24 (1.21, 1.28) 
African-American 1.41 (1.33, 1.50) 
Other/Unknown 1.43 (1.22, 1.67) 
50 European American 1.54 (1.47, 1.63) 
African-American 1.99 (1.76, 2.26) 
Other/Unknown 2.03 (1.49, 2.77) 
100 European American 2.39 (2.15, 2.64) 
African-American 3.96 (3.09, 5.09) 
Other/Unknown 4.14 (2.22, 7.69) 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
1
N presented for the main effect. 
2
Includes: lung, pancreatic, kidney, brain, bladder, liver, ovarian, esophageal, gastric cancers, and melanoma. 
2
 Cumulative sum of 







Table 4.30:  Duration of Sleep Disorder Diagnosis and Cancer Incidence Stratified by Co-morbid Diabetes Among Veterans in the SE 
USA (VISN-7, 1999-2010). 






 Hazard Ratio Confidence Interval 
All  1 Diabetes 37,760 1.01 (1.00, 1.01) 
No Diabetes 626,109 1.00 (1.00, 1.01) 
5 Diabetes  1.33 (1.06, 1.66) 
No Diabetes 1.23 (1.15, 1.31) 
10 Diabetes 1.76 (1.12, 2.77) 
No Diabetes 1.51 (1.32, 1.73) 
Prostate  1 Diabetes 35,978 1.00 (0.99, 1.01) 
No Diabetes 547,476 1.00 (1.00, 1.01) 
5 Diabetes  1.17 (0.78, 1.77) 
No Diabetes 1.25 (1.11, 1.39) 
10 Diabetes 1.38 (0.60, 3.14) 
No Diabetes 1.55 (1.24, 1.94) 
Colon  1 Diabetes 37,760 1.01 (1.00, 1.01) 
No Diabetes 626,109 1.00 (1.00, 1.01) 
5 Diabetes  1.65 (1.56, 2.35) 
No Diabetes 1.25 (1.10, 1.43) 
10 Diabetes 2.72 (1.34, 5.53) 
No Diabetes 1.57 (1.20, 2.04) 
Female Breast  1 Diabetes 1,545 0 (0, 0) 
No Diabetes 70,065 1.00 (0.99, 1.02) 
5 Diabetes  0 (0, 0) 
No Diabetes 1.23 (0.52, 2.91) 
10 Diabetes 0 (0, 0) 
No Diabetes 1.51 (0.27, 8.45) 
Other
2
 1 Diabetes 37,760 1.00 (0.99, 1.01) 










5 Diabetes  
 
 
1.21 (0.80, 1.82) 
No Diabetes 1.20 (1.07, 1.34) 
10 Diabetes 1.46 (0.65, 3.29) 
No Diabetes 1.43 (1.15, 1.79) 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
1
N presented are for the main effect. 
2







Table 4.31: Cumulative Sleep Disorder Treatment and Cancer Incidence Stratified by the Co-morbid Diabetes  
Among Veterans in the SE USA (VISN-7, 1999-2010). 









 Hazard Ratio 95% CI 
All 
 
Treatment  Diabetes 37,760 0.96 (0.95, 0.97) 
No Diabetes 626,109 0.96 (0.95, 0.96) 
Treatment*Time 1 Diabetes  1.01 (1.01, 1.01) 
No Diabetes 1.01 (1.01, 1.01) 
25  Diabetes 1.27 (1.21, 1.34) 
No Diabetes 1.26 (1.24, 1.29) 
50  Diabetes 1.62 (1.46, 1.80) 
No Diabetes 1.60 (1.54, 1.65) 
100  Diabetes 2.62 (2.12, 3.25) 
No Diabetes 2.55 (2.37, 2.73) 
Prostate  Treatment  Diabetes 35,978 0.95 (0.93, 0.96) 
No Diabetes 547,476 0.94 (0.94, 0.95) 
Treatment*Time 1 Diabetes  1.01 (1.01, 1.02) 
No Diabetes 1.01 (1.01, 1.01) 
25 Diabetes 1.33 (1.20, 1.47) 
No Diabetes 1.35 (1.30, 1.40) 
50 Diabetes 1.77 (1.44, 2.16) 
No Diabetes 1.82 (1.70, 1.96) 
100 Diabetes 3.12 (2.08, 4.68) 
No Diabetes 3.33 (2.90, 3.82) 
Colon  Treatment  Diabetes 37,760 0.97 (0.94, 1.00) 
No Diabetes 626,109 0.98 (0.98, 0.99) 
Treatment*Time 1 Diabetes  1.01 (0.99, 1.01) 
No Diabetes 1.00 (1.00, 1.01) 







Table 4.31: Cumulative Sleep Disorder Treatment and Cancer Incidence Stratified by the Co-morbid Diabetes  
Among Veterans in the SE USA (VISN-7, 1999-2010). 









 Hazard Ratio 95% CI 
No Diabetes 1.10 (1.05, 1.15) 
50 Diabetes 1.36 (0.97, 1.89) 
No Diabetes 1.21 (1.01, 1.32) 
100 Diabetes 1.85 (0.95, 3.59) 
No Diabetes 1.45 (1.21, 1.74) 
Female Breast   Treatment  Diabetes 1,545 1.09 (0.84, 1.40) 
No Diabetes 70,085 0.97 (0.95, 0.99) 
Treatment*Time 1 Diabetes  0.97 (0.91, 1.04) 
No Diabetes 1.01 (1.00, 1.01) 
25 Diabetes 0.49 (0.10, 1.58) 
No Diabetes 1.16 (1.02, 1.32) 
50 Diabetes 0.25 (0.01, 6.67) 
No Diabetes 1.34 (1.04, 1.75) 
100 Diabetes 0.06 (0, 44.45) 
No Diabetes 1.81 (1.07, 3.05) 
Other
2
 Treatment  Diabetes 37,760 0.96 (0.95, 0.98) 
No Diabetes 626,109 0.96 (0.95, 0.97) 
Treatment*Time 1 Diabetes  1.01 (1.01, 1.01) 
No Diabetes 1.01 (1.01, 1.01) 
25 Diabetes 1.23 (1.44, 1.32) 
No Diabetes 1.24 (1.22, 1.27) 
50 Diabetes 1.51 (1.31, 1.75) 
No Diabetes 1.55 (1.48, 1.62) 
100 Diabetes 2.29 (1.71, 3.05) 







Table 4.31: Cumulative Sleep Disorder Treatment and Cancer Incidence Stratified by the Co-morbid Diabetes  
Among Veterans in the SE USA (VISN-7, 1999-2010). 









 Hazard Ratio 95% CI 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
1
N presented for the main effect.  
2









Table 4.32:  Duration of Sleep Disorder Diagnosis and Cancer Incidence Stratified by Co-morbid Mental Disorders Among Veterans 
in the SE USA (VISN-7, 1999-2010). 




 Hazard Ratio 95% CI 
All 1 Mental Disorders or Mental Retardation 108,370 1.00 (0.99, 1.00) 
No Mental Disorders or Mental Retardation 555,499 1.00 (1.00, 1.01) 
5 Mental Disorders or Mental Retardation  1.03 (0.88, 1.19) 
No Mental Disorders or Mental Retardation 1.31 (1.22, 1.40) 
10 Mental Disorders or Mental Retardation 1.06 (0.78, 1.43) 
No Mental Disorders or Mental Retardation 1.70 (1.48, 1.97) 
Prostate  1 Mental Disorders or Mental Retardation 98,040 1.00 (0.99, 1.01) 
No Mental Disorders or Mental Retardation 485,414 1.00 (1.00, 1.01) 
5 Mental Disorders or Mental Retardation  1.12 (0.87, 1.44) 
No Mental Disorders or Mental Retardation 1.28 (1.13, 1.44) 
10 Mental Disorders or Mental Retardation 1.25 (0.76, 2.06) 
No Mental Disorders or Mental Retardation 1.63 (1.28, 2.07) 
Colon  1 Mental Disorders or Mental Retardation 108,370 0.99 (0.99, 1.00) 
No Mental Disorders or Mental Retardation 555,499 1.01 (1.00, 1.01) 
5 Mental Disorders or Mental Retardation  0.89 (0.64, 1.23 
No Mental Disorders or Mental Retardation 1.41 (1.24, 1.62) 
10 Mental Disorders or Mental Retardation 0.78 (0.41, 1.52) 
No Mental Disorders or Mental Retardation 1.99 (1.53, 2.61) 
Female Breast  1 Mental Disorders or Mental Retardation 9,404 1.00 (0.98, 1.03) 
No Mental Disorders or Mental Retardation 62,206 1.00  (0.98, 1.02) 
5 Mental Disorders or Mental Retardation  1.30 (0.27, 6.23) 
No Mental Disorders or Mental Retardation 1.10 (0.39, 3.13) 
10 Mental Disorders or Mental Retardation 1.68 (0.07, 38.79) 
No Mental Disorders or Mental Retardation 1.21 (0.15, 9.82) 
Other
2 
1 Mental Disorders or Mental Retardation 108,370 1.00 (0.99, 1.01) 







Table 4.32:  Duration of Sleep Disorder Diagnosis and Cancer Incidence Stratified by Co-morbid Mental Disorders Among Veterans 
in the SE USA (VISN-7, 1999-2010). 




 Hazard Ratio 95% CI 
5 Mental Disorders or Mental Retardation  
 
 
1.04 (0.82, 1.32) 
No Mental Disorders or Mental Retardation 1.26 (1.12, 1.42) 
10 Mental Disorders or Mental Retardation 1.08 (0.67, 1.74) 
No Mental Disorders or Mental Retardation 1.59 (1.26, 2.03) 
1
N presented for the main effect. 
2
Other Cancer includes: Lung, pancreatic, kidney, brain, bladder, liver, ovarian, esophageal, gastric, 









Table 4.33: Cumulative Sleep Disorder Treatment and Cancer Incidence Stratified by the Co-morbid Mental Disorders Among 
Veterans in the SE USA (VISN-7, 1999-2010). 













Treatment  Mental Disorders or Mental 
Retardation 
108,370 0.93 (0.92, 0.94) 
No Mental Disorders or 
Mental Retardation 
555,499 0.96 (0.96, 0.96) 
Treatment*Time 1 Mental Disorders or Mental 
Retardation 
 1.02 (1.01, 1.02) 
No Mental Disorders or 
Mental Retardation 
1.01 (1.01, 1.01) 
25  Mental Disorders or Mental 
Retardation 
1.45 (1.39, 1.51) 
No Mental Disorders or 
Mental Retardation 
1.24 (1.22, 1.26) 
50  Mental Disorders or Mental 
Retardation 
2.10 (1.93, 2.27) 
No Mental Disorders or 
Mental Retardation 
1.53 (1.48, 1.59) 
100  Mental Disorders or Mental 
Retardation 
4.39 (3.73, 5.17) 
No Mental Disorders or 
Mental Retardation 
2.35 (2.19, 2.53) 
Prostate  Treatment  Mental Disorders or Mental 
Retardation 
98,040 0.91 (0.89, 0.92) 
No Mental Disorders or 
Mental Retardation 
485,414 0.95 (0.94, 0.96) 








No Mental Disorders or 
Mental Retardation 
1.01 (1.01, 1.01) 
25 Mental Disorders or Mental 
Retardation 
1.64 (1.51, 1.78) 
No Mental Disorders or 
Mental Retardation 
1.31 (1.26, 1.36) 
50 Mental Disorders or Mental 
Retardation 
2.68 (2.28, 3.16) 
No Mental Disorders or 
Mental Retardation 
1.71 (1.59, 1.84) 
100 Mental Disorders or Mental 
Retardation 
7.18 (5.18, 9.97) 
No Mental Disorders or 
Mental Retardation 
2.92 (2.52, 3.37) 
Colon Treatment  Mental Disorders or Mental 
Retardation 
108,370 0.98 (0.96, 0.99) 
No Mental Disorders or 
Mental Retardation 
555,499 0.98 (0.97, 0.99) 
Treatment*Time 1 Mental Disorders or Mental 
Retardation 
 1.01 (1.00, 1.01) 
No Mental Disorders or 
Mental Retardation 
1.00 (1.00, 1.01) 
25 Mental Disorders or Mental 
Retardation 
1.13 (1.02, 1.25) 
No Mental Disorders or 
Mental Retardation 
1.10 (1.05, 1.16) 
50 Mental Disorders or Mental 
Retardation 
1.27 (1.03, 1.56) 








100 Mental Disorders or Mental 
Retardation 
1.61 (1.07, 2.43) 
No Mental Disorders or 
Mental Retardation 
1.48 (1.21, 1.80) 
Female Breast  Treatment  Mental Disorders or Mental 
Retardation 
9,404 0.95 (0.89, 1.01) 
No Mental Disorders or 
Mental Retardation 
62,206 0.98 (0.95, 1.00) 
Treatment*Time 1 Mental Disorders or Mental 
Retardation 
 1.01 (0.99, 1.03) 
No Mental Disorders or 
Mental Retardation 
1.01 (1.00, 1.01) 
25 Mental Disorders or Mental 
Retardation 
1.33 (0.95, 1.87) 
No Mental Disorders or 
Mental Retardation 
1.15 (0.99, 1.33) 
50 Mental Disorders or Mental 
Retardation 
1.77 (0.90, 3.51) 
No Mental Disorders or 
Mental Retardation 
1.32 (0.98, 1.78) 
100 Mental Disorders or Mental 
Retardation 
3.15 (0.80, 12.32) 
No Mental Disorders or 
Mental Retardation 
1.74 (0.95, 3.16) 
Other
2
 Treatment  Mental Disorders or Mental 
Retardation 
108,270 0.94 (0.93, 0.95) 
No Mental Disorders or 
Mental Retardation 
555,499 0.96 (0.96, 0.97) 










No Mental Disorders or 
Mental Retardation 
1.01 (1.01, 1.01) 
25 Mental Disorders or Mental 
Retardation 
1.40 (1.33, 1.48) 
No Mental Disorders or 
Mental Retardation 
1.22 (1.19, 1.25) 
50 Mental Disorders or Mental 
Retardation 
1.96 (1.76, 2.19) 
No Mental Disorders or 
Mental Retardation 
1.49 (1.42, 1.56) 
100 Mental Disorders or Mental 
Retardation 
3.86 (3.08, 4.83) 
No Mental Disorders or 
Mental Retardation 
2.22 (2.01, 2.45) 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
1
N presented are for the main effect.  
2
Includes: lung, pancreatic, kidney, brain, bladder, liver, ovarian, esophageal, gastric cancers, and melanoma. 
2
 Cumulative sum of 








Table 4.34:  Duration of Sleep Disorder Diagnosis and Cancer Incidence Stratified by Co-morbid Cardiovascular Disease, 
Hypertension, or Stroke Among Veterans in the SE USA (VISN-7, 1999-2010). 








All  1 Cardiovascular disease, hypertension, and stroke 219,247 1.00 (1.00, 1.01) 
No Cardiovascular disease, hypertension, or stroke 444,622 1.00 (1.00, 1.01) 
5 Cardiovascular disease, hypertension, and stroke  1.18 (1.06, 1.33) 
No Cardiovascular disease, hypertension, or stroke 1.29 (1.20, 1.40) 
10 Cardiovascular disease, hypertension, and stroke 1.39 (1.11, 1.76) 
No Cardiovascular disease, hypertension, or stroke 1.68 (1.44, 1.97) 
Prostate  1 Cardiovascular disease, hypertension, and stroke 206,716 1.00 (1.00, 1.01) 
No Cardiovascular disease, hypertension, or stroke 376,738 1.00 (1.00, 1.01) 
5 Cardiovascular disease, hypertension, and stroke  1.19 (0.98, 1.45) 
No Cardiovascular disease, hypertension, or stroke 1.29 (1.14, 1.47) 
10  Cardiovascular disease, hypertension, and stroke 1.41 (0.96, 2.09) 
No Cardiovascular disease, hypertension, or stroke 1.67 (1.29, 2.17) 
Colon 1 Cardiovascular disease, hypertension, and stroke 219,247 1.01 (1.00, 1.01) 
No Cardiovascular disease, hypertension, or stroke 444,622 1.00 (1.00, 1.01) 
5 Cardiovascular disease, hypertension, and stroke  1.36 (1.12, 1.66) 
No Cardiovascular disease, hypertension, or stroke 1.29 (1.10, 1.51) 
10 Cardiovascular disease, hypertension, and stroke 1.85 (1.25, 2.75) 
No Cardiovascular disease, hypertension, or stroke 1.66 (1.20, 2.28) 
Female Breast  1 Cardiovascular disease, hypertension, and stroke 11,043 0.93 (0.79, 1.09) 
No Cardiovascular disease, hypertension, or stroke 60,567 1.01 (0.99, 1.03) 
5 Cardiovascular disease, hypertension, and stroke  0.01 (0, 179.94) 
No Cardiovascular disease, hypertension, or stroke 1.92 (0.83, 4.44) 
10 Cardiovascular disease, hypertension, and stroke 0 (0, 32379.63) 







Table 4.34:  Duration of Sleep Disorder Diagnosis and Cancer Incidence Stratified by Co-morbid Cardiovascular Disease, 
Hypertension, or Stroke Among Veterans in the SE USA (VISN-7, 1999-2010). 










 1 Cardiovascular disease, hypertension, and stroke 219,247 1.00 (0.99, 1.00)  
No Cardiovascular disease, hypertension, or stroke 444,622 1.00 (1.00, 1.01) 
5 Cardiovascular disease, hypertension, and stroke  
 
 
1.07 (0.88, 1.31) 
No Cardiovascular disease, hypertension, or stroke 1.30 (1.14, 1.47) 
10 Cardiovascular disease, hypertension, and stroke 1.15 (0.78, 1.70) 
No Cardiovascular disease, hypertension, or stroke 1.68 (1.30, 2.17) 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
1
N presented are for the main effect.  
2









Table 4.35: Cumulative Sleep Disorder Treatment and Cancer Incidence Stratified by the Co-morbid Cardiovascular Disease, 
Hypertension, and Stroke Among Veterans in the SE USA (VISN-7, 1999-2010). 











All Treatment  Cardiovascular disease, hypertension, 
and stroke 
219,247 0.95 (0.95, 0.96) 
No Cardiovascular disease, 
hypertension, or stroke 
444,622 0.96 (0.95, 0.96) 
Treatment*Time 1 Cardiovascular disease, hypertension, 
and stroke 
 1.01 (1.01, 1.01) 
No Cardiovascular disease, 
hypertension, or stroke 
1.01 (1.01, 1.01) 
25  Cardiovascular disease, hypertension, 
and stroke 
1.28 (1.25, 1.31) 
No Cardiovascular disease, 
hypertension, or stroke 
1.26 (1.23, 1.29) 
50  Cardiovascular disease, hypertension, 
and stroke 
1.64 (1.56, 1.72) 
No Cardiovascular disease, 
hypertension, or stroke 
1.58 (1.51, 1.66) 
100  Cardiovascular disease, hypertension, 
and stroke 
2.69 (2.44, 2.97) 
No Cardiovascular disease, 
hypertension, or stroke 
2.51 (2.29, 2.75) 
Prostate  Treatment  Cardiovascular disease, hypertension, 
and stroke 
206,716 0.94 (0.93, 0.95) 
No Cardiovascular disease, 
hypertension, or stroke 
376,738 0.95 (0.94, 0.96 








No Cardiovascular disease, 
hypertension, or stroke 
1.01 (1.01, 1.01) 
25 Cardiovascular disease, hypertension, 
and stroke 
1.39 (1.32, 1.46) 
No Cardiovascular disease, 
hypertension, or stroke 
1.32 (1.27, 1.38) 
50 Cardiovascular disease, hypertension, 
and stroke 
1.93 (1.74, 2.13) 
No Cardiovascular disease, 
hypertension, or stroke 
1.75 (1.60, 1.91) 
100 Cardiovascular disease, hypertension, 
and stroke 
3.71 (3.04, 4.53) 
No Cardiovascular disease, 
hypertension, or stroke 
3.07 (2.57, 3.66) 
Colon  Treatment  Cardiovascular disease, hypertension, 
and stroke 
219,247 0.98 (0.97, 0.99) 
No Cardiovascular disease, 
hypertension, or stroke 
444,622 0.98 (0.97, 0.99) 
Treatment*Time 1 Cardiovascular disease, hypertension, 
and stroke 
 1.00 (1.00, 1.01) 
No Cardiovascular disease, 
hypertension, or stroke 
1.00 (1.00, 1.01) 
25 Cardiovascular disease, hypertension, 
and stroke 
1.10 (1.03, 1.18) 
No Cardiovascular disease, 
hypertension, or stroke 
1.11 (1.04, 1.17) 
50 Cardiovascular disease, hypertension, 
and stroke 
1.22 (1.06, 1.39) 







hypertension, or stroke 
100 Cardiovascular disease, hypertension, 
and stroke 
1.48 (1.13, 1.93) 
No Cardiovascular disease, 
hypertension, or stroke 
1.49 (1.18, 1.89) 
Female Breast   Treatment  Cardiovascular disease, hypertension, 
and stroke 
11,043 0.96 (0.92, 0.99) 
No Cardiovascular disease, 
hypertension, or stroke 
60,567 0.98 (0.94, 1.01) 
Treatment*Time 1 Cardiovascular disease, hypertension, 
and stroke 
 1.01 (1.00, 1.02) 
No Cardiovascular disease, 
hypertension, or stroke 
1.01 (0.99, 1.01) 
25 Cardiovascular disease, hypertension, 
and stroke 
1.25 (0.99, 1.57) 
No Cardiovascular disease, 
hypertension, or stroke 
1.15 (0.95, 1.39) 
50 Cardiovascular disease, hypertension, 
and stroke 
1.57 (0.99, 2.46) 
No Cardiovascular disease, 
hypertension, or stroke 
1.32 (0.90, 1.94) 
100 Cardiovascular disease, hypertension, 
and stroke 
2.45 (0.99, 6.03) 
No Cardiovascular disease, 
hypertension, or stroke 
1.75 (0.82, 3.75) 
Other
2
 Treatment  Cardiovascular disease, hypertension, 
and stroke 
219,247 0.96 (0.95, 0.96) 
No Cardiovascular disease, 
hypertension, or stroke 
444,622 0.96 (0.95, 0.97) 











No Cardiovascular disease, 
hypertension, or stroke 
1.01 (1.00, 1.01) 
25 Cardiovascular disease, hypertension, 
and stroke 
1.26 (1.22, 1.29) 
No Cardiovascular disease, 
hypertension, or stroke 
1.24 (1.20, 1.28) 
50 Cardiovascular disease, hypertension, 
and stroke 
1.58 (1.48, 1.68) 
No Cardiovascular disease, 
hypertension, or stroke 
1.53 (1.44, 1.63) 
100 Cardiovascular disease, hypertension, 
and stroke 
2.48 (2.18, 2.83) 
No Cardiovascular disease, 
hypertension, or stroke 
2.34 (2.07, 2.66) 
Adjusted for: marital status, state or residence, sex (except for gender specific cancers), and age. 
1 
N presented for the main effect. 
2
Includes: lung, pancreatic, kidney, brain, bladder, liver, ovarian, esophageal, gastric cancers, and melanoma. 
2
 Cumulative sum of 





DISCUSSION AND CONCLUSIONS 
The major findings of this study were increased cancer risk with sleep disorder 
diagnosis with evidence of increasing risk with longer durations of sleep disorder 
exposure, or more sleep disorder-related cumulative treatments, which was used as a 
possible surrogate measure of sleep disorder severity. Extended Cox adjusted models for 
cancer incidence with time-varying sleep disorder exposure reflect an increase risk of all, 
prostate, colon, and other cancers among those with sleep disorders. Our results are 
similar to those of other studies that have found an increased risk of cancer which used 
extremes in the length of sleep instead of a clinical sleep disorder diagnosis, including 
short sleep durations for colon [111, 112], general [108], breast [118], and prostate [121] 
cancer, and long sleep durations for colon [110, 111] and breast [119] cancer compared to 
those with normal sleep durations ranging from six to eight hours. Other studies had 
study populations that were predominantly women in contrast to our predominantly male 
population. This study’s results also were similar to studies that identified a higher 
incidence of cancer in populations with sleep disorders [40, 120, 144]. Hu, et al. noted a 
hazard ratio of 1.19 (95% CI: 1.14, 1.24) for non-apnea sleep disorder cancer risk among 
their study population, which was primarily women with a median age of 44 [40]. For 
PCa risk, Sigurdardottir, et al. reported a hazard ratio of 1.7 (95% CI: 1.0, 2.9) among 
those who indicated they had problems falling asleep on questionnaires and an even 




increased severity of sleep disruption, which compares to the hazard ratio found in this 
study of 1.5 (95% CI:1.37, 1.64) for any sleep disorder [120]. Hazard ratios for any sleep 
disorder in were between 1.34 and 1.69 for the cancer risk group among veterans in the 
present study, which are similar to the other noted studies. In addition, the increase in 
cancer risk among veterans in this study with a sleep apnea diagnosis was similar to other 
studies among those with moderate to severe sleep apnea [107, 109]. 
 
  
Results from this study also indicate that cancer risk increased with increasing 
sleep disorder duration. There were incremental increases in the hazard ratios for each 
type of cancer evaluated as sleep disorder duration increased from 1 to 10 years, which 
suggests a possible dose-response relationship between sleep disorder duration and 
cancer incidence.  We evaluated the risk of cancer incidence at 1, 5, and 10 years of 
duration, noting increases in cancer hazard ratios ranging from 1.04 to 1.05 after 1 year of 
diagnosis and increased to 1.52 to 1.65 after 10 years of sleep disorder duration. An 
increasing risk of each cancer outcome also was observed among those with an 
increasing number of sleep disorder prescriptions and/or procedures, which may be 
interpreted as an increase in cancer risk with increasing sleep disorder severity. This also 
may suggest a dose-response relationship between sleep disorders and cancer incidence. 
Unfortunately, the number of sleep disorder prescriptions and procedures is only a 
surrogate for sleep disorder severity, and other interpretations are possible. For example, 
more treatment may correspond to better managed sleep disorders, or it may suggest an 
iatrogenic effect or reverse causality of prescription sleep disorder medications on cancer 
risk, which has been suggested previously [145, 146]. Further research is necessary to 




the higher cumulative treatments (primarily prescriptions for sleep medications) are 
carcinogenic, which has been suggested in some studies [145]. Few studies have focused 
on sleep disorder duration or severity in conjunction with cancer risk, thus additional 
research is needed to confirm and extend these observations.  
A strength of this study was the use of clinically diagnosed sleep disorders as 
opposed to self-reported sleep disruption, which was commonly used in previous studies. 
In addition, the analysis of sleep disorder duration is one of the first to assess the long 
term impacts of sleep disorders. Other studies have evaluated the duration of sleep during 
the night in relation to disease [104, 106, 108, 110-112, 114-118, 121], but not the 
amount of time individuals have suffered from the condition.  
This study was limited to information only among veterans seeking care through 
the Department of Veteran Affairs health care system in the southeastern US. Thus, the 
generalizability of the results to other populations or geographic areas was limited. Also, 
veterans who did not visit a VA healthcare center were not included in the analysis. 
Exclusion of those who transition out of the VA healthcare system could have caused a 
selection bias in this study. The VA population, though quite large with electronic 
medical records available for use, has unique demographic characteristics relative to non-
veteran populations, making it difficult to generalize the results to the US population. In 
addition, our analysis was limited by the lack of information related to several known 
cancer risk factors, including body mass index [140], smoking status, and social 
economic status. In addition, the presence of undiagnosed sleep disorders may have 
biased our results towards the null. Finally, it is possible that a pre-diagnostic or occult 




resulted in a reverse causality scenario. However, the results obtained from analyses of 
sleep disorder duration make this an unlikely issue as there was a noted increased cancer 
risk with longer sleep disorder durations.  
Despite these limitations, this study had a robust sample size and is one of the few 
[40] to evaluate the cancer risk using clinically diagnosed sleep disorders and clinical 
treatments, as opposed to self-reported or short-term characterization of sleep disruption. 
Also, no other studies have assessed the effect of the duration of exposure to a sleep 
disorder over time. Though there are other studies that examined the relationship between 
of sleep medication use disorder treatment [146, 147], none were found that evaluated the 
cumulative effect of all such treatments on cancer incidence. No other studies evaluating 
sleep disorder exposure and cancer incidence in a Veteran population were identified that 
specifically evaluated the effects of post-traumatic stress disorder with sleep disruption as 
a symptom. 
There was a noticeable increasing trend of sleep disorders diagnosed during the 
study period. The incidence of sleep disorders diagnosed in 2010 was more than double 
the number diagnosed in 1999. In particular, the number of apnea sleep disorders 
diagnosed in 2010 was triple that of 1999 at the beginning of the study. It is unclear if 
this increase in clinically diagnosed sleep disorders was due to a true increase in 
incidence of disease or just an increase in physician awareness leading to more clinically 
diagnosed cases. Sleep disorders were identified in 7% of the study population with sleep 





 Stratified analysis by diabetes, mental disorders, hypertension, cardiovascular 
disease, or stroke status did not indicate higher rates of cancer incidence among those 
suffering from these co-morbid conditions compared to those without co-morbid disease. 
We observed only modest differences in cancer incidence in the race stratified models for 
all sleep disorders with AA and EA having similar hazard ratios for all cancer and 
prostate cancer, but the other/unknown race group having higher risks. For colon cancer, 
only the EA strata had a statistically significant hazard ratio for cancer among those with 
any sleep disorders. When the effects of sleep disorder duration were stratified by race, 
similar increases in hazard ratios for all cancer were observed for both EA and AA 
participants, although no increases were observed among those in the other/unknown race 
group. When cumulative treatments were evaluated by race, AAs and the other/unknown 
race group had higher hazard ratios compared to EAs. Further research is needed to 
determine whether the impact of sleep disorders on cancer incidence does in fact vary 
between race groups. 
  The results of this study suggest a link between sleep disorder diagnoses and 
cancer incidence.  In particular, those who are exposed longer or receive more treatments 
for a sleep disorder may be at the greatest risk of cancer development. The results may 
have clinical implications for examining the type and quantity of treatment offered as it 
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